Publications and communications of Jerusalem, Guy

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (In press). Randomized-controlled trial of an intervention combining self-care and self-hypnosis on fatigue, sleep and emotional distress in post-treatment cancer patients: 1-year follow up. International Journal of Clinical and Experimental Hypnosis. doi:10.1080/00207144.2022.2049973

Kirkove, D.* , STREEL, S.* , ORY, A., AUBOUY, G., DE JODE, E., JERUSALEM, G., GAGNAYRE, R., & Pétré, B. (May 2022). Immuno’Act - J’agis sur les effets secondaires liés à mon immunothérapie oncologique. Poster session presented at Congrès Éducation Thérapeutique du Patient 2022, Montpellier, France.

Grégoire, C., Marie, N., Sombrun, C., FAYMONVILLE, M.-E., Kotsou, I., Van Nitsen, V., De Ribaucourt, S., JERUSALEM, G., LAUREYS, S., VANHAUDENHUYSE, A.* , & Gosseries, O.*. (2022). Hypnosis, meditation and self-induced cognitive trance to improve post-treatment oncological patients’ quality of life: study protocol. Frontiers in Psychology. doi:10.3389/fpsyg.2022.807741

JERUSALEM, G., Delea, T. E., Martin, M., De Laurentiis, M., Nusch, A., Beck, J. T., Chan, A., Im, S.-A., Neven, P., Lonshteyn, A., Chandiwana, D., Lanoue, B., & Fasching, P. A. (13 January 2022). Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2-Advanced Breast Cancer in the Monaleesa-3 Trial. Clinical Breast Cancer, 14 (14), 1-10. doi:10.1016/j.clbc.2021.12.008

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., & Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571

Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (07 July 2021). Effets d’une intervention basée sur l’hypnose sur la fatigue, le sommeil et la détresse de patients oncologiques. Paper presented at 11ème Congrès de l’Association Francophone de Psychologie de la Santé.

Uyisenga, J. P.* , Debit, A.* , Poulet, C., Frères, P., Poncin, A., Thiry, J., Mutesa, L., Jerusalem, G., Bours, V.* , & JOSSE, C.*. (03 June 2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports, 11 (1), 11698. doi:10.1038/s41598-021-91278-0

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T.-W., Pieńkowski, T., Toi, M., Wilcken, N., Andersson, M., Im, Y.-H., Tseng, L. M., & Thomssen, C. (29 April 2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (13), 1448-1457. doi:10.1200/JCO.20.01204

GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Willems, S., & Bragard, I. (11 February 2021). Exploratory controlled study of the impact of a hypnosis-based intervention on the couple’s communication and coping in the context of cancer. International Journal of Clinical and Experimental Hypnosis, 69 (2), 261-276. doi:10.1080/00207144.2021.1878897

GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (February 2021). Randomized-controlled trial of a group intervention combining self-hypnosis and self-care: secondary results on self-esteem, emotional distress and regulation, and mindfulness in post-treatment cancer patients. Quality of Life Research, 30, 425-436. doi:10.1007/s11136-020-02655-7

Chiavarina, B., Costanza, B., Ronca, R., Blomme, A., Rezzola, S., Chiodelli, P., Giguelay, A., Belthier, G., Doumont, G., Van Simaeys, G., Lacroix, S., Yokobori, T., Erkhem-Ochir, B., Balaguer, P., Cavailles, V., Fabbrizio, E., Di Valentin, E., Gofflot, S., Detry, O., & Turtoi, A. (January 2021). Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis. Theranostics, 11 (4), 1626-1640. doi:10.7150/thno.51507

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646

Jossa, V., Olivier, F., LIFRANGE, E., Crevecoeur, A., COURTOIS, A., Coibion, M., & JERUSALEM, G. (2021). From modified radical mastectomy to infra-radical mastectomy: A phase I study for surgical de-escalation focusing on pathological analyses. Gland Surgery. doi:10.21037/gs-21-48

Lodewijckx, E., Kenis, C., Flamaing, J., Debruyne, P., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., & Decoster, L. (2021). Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. Journal of Geriatric Oncology, 12 (3), 368-374. doi:10.1016/j.jgo.2020.11.004

Onesti, C. E., & Jerusalem, G. (2021). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21 (3), 283-298. doi:10.1080/14737140.2021.1852934

ONESTI, C. E., Tagliamento, M., Curigliano, G., Harbeck, N., Bartsch, R., Wildiers, H., Tjan-Heijnen, V., Martin, M., Rottey, S., Generali, D., Campone, M., Cristofanilli, M., Pusztai, L., Peeters, M., Berchem, G., Cortes, J., Ruhstaller, T., Ciruelos, E., Rugo, H. S., & Jerusalem, G. (2021). Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology, 7, 162-172. doi:10.1200/GO.20.00589

Pilard, C.* , Ancion, M.* , Delvenne, P., JERUSALEM, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 125(7), 927-938. doi:10.1038/s41416-021-01413-x

SCHEEN, A., BEGUIN, Y., & JERUSALEM, G. (2021). L’oncologie, à un tournant de son histoire. Revue Médicale de Liège, 76, 297-299.

Schettini, F., Giuliano, M., Giudici, F., Conte, B., De Placido, P., Venturini, S., Rognoni, C., Di Leo, A., Locci, M., Jerusalem, G., Del Mastro, L., Puglisi, F., Conte, P., De Laurentiis, M., Pusztai, L., Rinmawi, M. F., Schiff, R., Arpino, G., De Placido, S., & Generali, D. (2021). Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 13 (6), 1458 (21. doi:10.3390/cancers13061458

Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., ONESTI, C. E., Harbeck, N., Rottey, S., Van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., & Generali, D. (2021). Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13 (17), 4421. doi:10.3390/cancers13174421

Schmid, P., Sablin, M.-P., Bergh, J., Im, S.-A., Lu, Y.-S., Martínez, N., Neven, P., Lee, K. S., Morales, S., Pérez-Fidalgo, J. A., Adamson, D., Gonçalves, A., Prat, A., Jerusalem, G., Schlieker, L., Espadero, R.-M., Bogenrieder, T., Huang, D. C.-L., Crown, J., & Cortés, J. (2021). A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast cancer research : BCR, 23 (1), 8. doi:10.1186/s13058-020-01382-8

Onesti, C. E., JOSSE, C., Boulet, D., Bours, V., & JERUSALEM, G. (2020). High plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer. Tumori Journal.

ONESTI, C. E., JOSSE, C., Beaumecker, B., Boulet, D., Thiry, J., BOURS, V., & JERUSALEM, G. (2020). The relative eosinophil count in breast cancer as an emerging prognostic biomarker. European Journal of Cancer. doi:10.1016/S0959-8049(20)30766-8

Guerini-Rocco, E., Gray, K. P., Fumagalli, C., Reforgiato, M. R., Leone, I., Rafaniello Raviele, P., Munzone, E., Kammler, R., Neven, P., Hitre, E., Jerusalem, G., Simoncini, E. L., Gombos, A., Deleu, I., Karlsson, P., Aebi, S., Chirgwin, J., Di Lauro, V., Thompson, A. M., & Colleoni, M. (2020). Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. doi:10.1158/1078-0432.CCR-20-0126

JERUSALEM, G., ONESTI, C. E., Generali, D., Harbeck, N., Wildiers, H., Curigliano, G., Campone, M., Tjan-Heijnen, V., Martin, M., Cristofanilli, M., Pusztai, L., Bartsch, R., Peeters, M., Berchem, G., Tagliamento, M., Cortès, J., Ruhsthaller, T., Ciruelos, E., Rottey, S., & Rugo, H. (2020). Expected medium and long term impact of the COVID-19 outbreak in oncology. Annals of Oncology.

ONESTI, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., & JERUSALEM, G. (August 2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5. doi:10.1136/esmoopen-2020-000853

GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Willems, S., & Bragard, I. (July 2020). Effects of an intervention combining self-care and self-hypnosis on fatigue and associated symptoms in post-treatment cancer patients: A randomized-controlled trial. Psycho-oncology, 29 (7), 1165-1173. doi:10.1002/pon.5395

Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., & Wildiers, H. (July 2020). The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors. Journal of Geriatric Oncology, 11 (6), 926-936. doi:10.1016/j.jgo.2020.03.017

Jouret, G., GONNE, E., QUATRESOOZ, P., REGINSTER, M.-A., COLLINS, P., LEBAS, E., JERUSALEM, G., & NIKKELS, A. (2020). Cutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX). Dermatology and Therapy. doi:10.1007/s13555-020-00393-9

Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Del Mastro, L., Puglisi, F., De Placido, S., Paris, I., De Placido, P., Venturini, S., De Laurentis, M., Conte, P., Juric, D., Llombart-Cussac, A., Pusztai, L., Prat, A., Jerusalem, G., Di Leo, A., & Generali, D. (2020). Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. Journal of the National Cancer Institute. doi:10.1093/jnci/djaa071

POTTIER, C., Fresnais, M., Gilon, M., JERUSALEM, G., Longuespée, R.* , & Sounni, N. E.*. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers. doi:10.3390/cancers12030731

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., Barbeaux, A., Forget, F., KRIDELKA, F., & JERUSALEM, G. (February 2020). Impact of hemoglobin level and red blood cell transfusions in patients with locally advanced cervical cancer treated by chemoradiotherapy. Poster session presented at 22nd Annual BSMO meeting, Gent, Belgium.

Ciruelos, E., Jerusalem, G., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J., Montemurro, F., Generali, D., Lang, I., Martínez-Serrano, M. J., Perelló, M. F., & Conte, P. (2020). Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 22 (10), 1857-1866. doi:10.1007/s12094-020-02327-5

Corona, S. P., Giudici, F., JERUSALEM, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., Barbieri, G., Cervoni, V., Montemurro, F., & Generali, D. (2020). Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus : a retrospective exploratory analysis of the BALLET study. Oncotarget, 11 (23), 2172-2181. doi:10.18632/oncotarget.27612

Fasching, P. A., Beck, J. T., Chan, A., De Laurentiis, M., Esteva, F. J., Jerusalem, G., Neven, P., Pivot, X., Bianchi, G. V., Martin, M., Chandiwana, D., Lanoue, B., Ridolfi, A., Wang, Y., Rodriguez Lorenc, K., & Nusch, A. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. Breast (Edinburgh, Scotland), 54, 148-154. doi:10.1016/j.breast.2020.09.008

Gennigens, C., DE CUYPERE, M., SEIDEL, L., HERMESSE, J., Barbeaux, A., Forget, F., Albert, A., Jerusalem, G., & Kridelka, F. (2020). Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. Cancer Medicine, 1-12. doi:10.1002/cam4.3465

Hamilton, E., Cortes, J., Ozyilkan, O., Chen, S.-C., Petrakova, K., Manikhas, A., Jerusalem, G., Hegg, R., Huober, J., Chapman, S. C., Lu, Y., Hardebeck, M. C., Bear, M. M., Johnston, E. L., & Martin, M. (2020). nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clinical Breast Cancer. doi:10.1016/j.clbc.2020.09.011

JERUSALEM, G. (2020). Organisation des soins en cancérologie dans le contexte de la COVID-19 : expérience au CHU de Liège. Revue Médicale de Liège. Supplément, 75, 38-S40.

LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium. Poster session presented at ESMO Virtual Congress 2020, Madrid, Spain.

Neven, P., Sonke, G. S., & Jerusalem, G. (2020). Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Review of Anticancer Therapy, 1-14. doi:10.1080/14737140.2021.1840360

ONESTI, C. E., JOSSE, C., Boulet, D., Thiry, J., Beaumecker, B., BOURS, V., & JERUSALEM, G. (2020). Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. doi:10.1080/2162402X.2020.1761176

ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium. Poster session presented at ESMO Virtual Congress 2020, Madrid, Spain.

PONCIN, A., & Jerusalem, G. (2020). Evolution des thérapies anti-cancéreuses systémiques. Revue Médicale de Liège, 75 (5-6), 466-472.

Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M.-P., Rabaglio, M., Francis, P. A., Foukakis, T., & Bernhard, J. (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 122 (7), 1119. doi:10.1038/s41416-019-0709-x

Schettini, F., Sobhani, N., Ianza, A., Triulzi, T., Molteni, A., Lazzari, M. C., Strina, C., Milani, M., Corona, S. P., Sirico, M., Bernocchi, O., Giudici, F., Cappelletti, M. R., Ciruelos, E., Jerusalem, G., Loi, S., Fox, S. B., & Generali, D. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment, 184 (2), 421-431. doi:10.1007/s10549-020-05856-3

Schroyen, S., Letenneur, L., Missotten, P., Jerusalem, G., & Adam, S. (2020). Impact of self-perception of aging on mortality of older patients in oncology. Cancer Medicine, 9, 2283-2289. doi:10.1002/cam4.2819

Slamon, D. J., & Jerusalem, G. (2020). Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. The New England journal of medicine, 382 (23), 85. doi:10.1056/NEJMc2004229

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., & Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 382 (6), 514-524. doi:10.1056/NEJMoa1911149

Verschraegen, C. F., Jerusalem, G., McClay, E. F., Iannotti, N., Redfern, C. H., Bennouna, J., Chen, F. L., Kelly, K., Mehnert, J., Morris, J. C., Taylor, M., Spigel, D., Wang, D., Grote, H. J., Zhou, D., Munshi, N., Bajars, M., & Gulley, J. L. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer, 8 (2). doi:10.1136/jitc-2020-001064

Grégoire, C., Faymonville, M.-E., VANHAUDENHUYSE, A., CHARLAND-VERVILLE, V., Jerusalem, G., Dardenne, N., & Bragard, I. (26 September 2019). Effects of a hypnosis-based intervention on fatigue and sleep difficulties in post-treatment cancer patients. Poster session presented at 21st World Congress of Psycho-Oncology, Banff, Canada.

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Dardenne, N., & Bragard, I. (September 2019). Effects of a hypnosis-based intervention on fatigue and sleep difficulties in post-treatment cancer patients. Journal of Psychosocial Oncology Research and Practice, 1 (1S).

Goosse, M., Ortiz Halabi, I., BARTHELEMY, N., Guillaume, M., GHUYSEN, A., JERUSALEM, G., & Bragard, I. (10 July 2019). A virtual patient to enhance physicians training in breaking bad news in oncology. Paper presented at Simulation Congress 2019, Liege, Belgium.

Bicego, A. Y., GREGOIRE, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., LAUREYS, S., Bragard, I., & VANHAUDENHUYSE, A. (08 July 2019). Study of the impact of non-pharmacological techniques (self-hypnosis/self-care) on cognitive complaints in cancer patients. Paper presented at 15th European Conference on Psychological Assessment.

Goosse, M., Ortiz Halabi, I., BARTHELEMY, N., Guillaume, M., GHUYSEN, A., JERUSALEM, G., & Bragard, I. (12 June 2019). Methodology of a virtual patient development to enhance physicians training in breaking bad news in oncology. Paper presented at Sesam annual meeting, Glasgow, United Kingdom.

Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., Laureys, S., Bragard, I., & VANHAUDENHUYSE, A. (30 May 2019). Study of the impact of non-pharmacological techniques (self-hypnosis/self-care) on cognitive complaints in cancer patients. Paper presented at Hypnosis New Generation, Budapest, Hungary.

Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., LAUREYS, S., Bragard, I., & VANHAUDENHUYSE, A. (14 May 2019). Learning self-hypnosis/self-care improves cognitive complaints in cancer patients. Poster session presented at Annual Meeting of the Belgian Association for Psychological Sciences, Liège, Belgium.

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., Poulet, C., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome. Annals of Oncology.

Debit, A., Poulet, C., JOSSE, C., Azencott, C.-A., Jerusalem, G., Van Steen, K., & BOURS, V. (15 March 2019). TOWARDS AN ACCURATE CANCER DIAGNOSIS MODELIZATION:COMPARISON OF RANDOM FOREST STRATEGIES. Poster session presented at 19th BeSHG meeting 15th March 2019 Liege, Belgium, Liege, Belgium.

Latge, G., Poulet, C., JOSSE, C., JERUSALEM, G., & Bours, V. (15 March 2019). Role of DNA methylation in INK4a-ARF-INK4b locus expression in breast cancer. Poster session presented at 19th Meeting of the Belgian Society of Human Genetics, Liège, Belgium.

Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S.-H. I., Hellmann, M. D., Kim, S.-W., Ahn, M.-J., Kim, D.-W., Gutierrez, M., Liu, S. V., Schoffski, P., Jager, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabro, L., Weiss, J., Gadgeel, S., & Segal, N. H. (2019). Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 (10), 1794-1806. doi:10.1016/j.jtho.2019.06.010

Awada, A., Gligorov, J., Jerusalem, G., Preusser, M., Singer, C., & Zielinski, C. (2019). CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion. ESMO Open, 4 (6), 000565. doi:10.1136/esmoopen-2019-000565

Decoster, L., Quinten, C., Kenis, C., Flamaing, J., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., & Wildiers, H. (2019). Health related quality of life in older patients with solid tumors and prognostic factors for decline. Journal of Geriatric Oncology. doi:10.1016/j.jgo.2019.03.018

FOIDART, P., Yip, C., Radermacher, J., Blacher, S., Lienard, M., MONTERORUIZ, L., Maquoi, E., Montaudon, E., Chateau-Joubert, S., COLLIGNON, J., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E.* , & JERUSALEM, G.*. (2019). Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-18-1880

GENNIGENS, C., & JERUSALEM, G. (2019). State of the art in the treatment of soft tissue sarcomas. Belgian Journal of Medical Oncology, 13 (6), 227-233.

GENNIGENS, C., KRIDELKA, F., JERUSALEM, G., SEIDEL, L., GOFFIN, F., Barbeaux, A., Forget, F., KAKKOS, A., HERMESSE, J., GONNE, E., & DE CUYPERE, M. (2019). Lymphocytes count at diagnosis is a potential survival predictor in patients treated by chemoradiation in locally advanced cervical cancer. Poster session presented at ESGO 2019 Athens: 21st European Gynaecological Oncology Congress 2019, Athens, Greece.

Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., De Laurentiis, M., Thomas, G., De Placido, P., Arpino, G., De Placido, S., Cristofanilli, M., Giordano, A., Puglisi, F., Pistilli, B., Prat, A., Del Mastro, L., Venturini, S., & Generali, D. (2019). Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncology, 20, 1360-1369. doi:10.1016/S1470-2045(19)30420-6

Jerusalem, G., Lancellotti, P., & Kim, S.-B. (2019). HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Research and Treatment. doi:10.1007/s10549-019-05303-y

Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Goncalves, A., JERUSALEM, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., & Pickett, C. A. (2019). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 19 (1), 47-57. doi:10.1016/j.clbc.2018.09.012

Kirschbrown, W. P., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., Fumagalli, D., McConnell, R., JERUSALEM, G., Twelves, C., Baselga, J., von Minckwitz, G., Bines, J., & Garg, A. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6), 1147-1158. doi:10.1007/s00280-019-03826-1

Lancellotti, P., Suter, T. M., Lopez-Fernandez, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J.-L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. European Heart Journal. doi:10.1093/eurheartj/ehy453

Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., JERUSALEM, G., Bartsch, R., Rabaglio-Poretti, M., Kammler, R., Maibach, R., Smyth, M. J., Di Leo, A., Colleoni, M., Viale, G., Regan, M. M., & International Breast Cancer Study Group and the Breast International Group. (2019). Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncology, 20 (3), 371-382. doi:10.1016/S1470-2045(18)30812-X

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. Journal of Translational Medicine, 17, 239. doi:10.1186/s12967-019-1984-2

ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47

Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., & Wildiers, H. (2019). Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. Quality of Life Research, 28 (3), 663-676. doi:10.1007/s11136-018-2062-6

Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J. H., Aebi, S., JERUSALEM, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M.-P., Rabaglio, M., Francis, P. A., Foukakis, T., & on behalf of the SOLE Investigators. (2019). Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 120, 959-967. doi:10.1038/s41416-019-0435-4

Rolfo, C., de Vos-Geelen, J., Isambert, N., Molife, L. R., Schellens, J. H. M., De Grève, J., Dirix, L., Grundtvig-Sørensen, P., JERUSALEM, G., Leunen, K., Mau-Sørensen, M., Plummer, R., Learoyd, M., Bannister, W., Fielding, A., & Ravaud, A. (2019). Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics. doi:10.1007/s40262-019-00754-4

Van Ryckeghem, F., Haverbeke, C., Wynendaele, W., JERUSALEM, G., Somers, L., Van den broeck, A., Vingerhoedt, S., & Van Belle, S. (2019). Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. Supportive Care in Cancer, 27, 1099-1108. doi:10.1007/s00520-018-4399-3

Grégoire, C., Faymonville, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., Jerusalem, G., & Bragard, I. (15 November 2018). Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol. BMC Cancer, 18 (1113). doi:10.1186/s12885-018-5046-6

Debit, A., Poulet, C., JOSSE, C., Van Steen, K., JERUSALEM, G., Bours, V., & Azencott, C.-A. (05 October 2018). Towards an accurate cancer diagnosis modelization: Comparison of Random Forest strategies. Poster session presented at 5th conference Bioinformatics for young international researchers expo byteMAL 2018, Liege, Belgium.

LECLERC, A.-F., Slomian, J., JERUSALEM, G., COUCKE, P., BURY, T., Deflandre, D., DEVOS, M., Bruyère, O., Foidart-Dessalle, M., KAUX, J.-F., Crielaard, J.-M., & Maquet, D. (October 2018). Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up. Clinical Breast Cancer, 18 (5), 1189-e1204. doi:10.1016/j.clbc.2018.05.004

Neven, P., Petrakova, K., Bianchi, G. V., De La Cruz Merino, L., JERUSALEM, G., Beck, J. T., Sonke, G. S., Chia, S., Brucker, S., Wang, Y., He, W., Rodriguez Lorenc, K., Su, F., & Im, S.-A. (October 2018). Ribociclib + Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3 biomarker analyses. Annals of Oncology, 29 (supplement 8), 113 - viii 114.

ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120

Debit, A., JOSSE, C., JERUSALEM, G., BOURS, V., & Poulet, C. (13 September 2018). Towards an accurate cancer diagnosis modelization:Comparison of Random Forest strategies. Poster session presented at JOINT MEETING GIGA-CANCER DAY 2018 / EDT-CANCEROLOGY, Liege, Belgium.

Latgé, G., JOSSE, C., Poulet, C., Bours, V., & Jerusalem, G. (13 September 2018). Role of DNA methylation in INK4a-ARF-INK4b locus expression in breast cancer. Poster session presented at GIGA-Cancer DAY, Liege, Belgium.

ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment. Paper presented at GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology.

Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., Guesquière, B., Karim, L., Charloteaux, B., Jamart, D., Florin, A., Lambert, C., RORIVE, A., JERUSALEM, G., Leucci, E., & Close, P. (28 June 2018). Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 558, 605-609. doi:10.1038/s41586-018-0243-7

Kenis, C., Decoster, L., Flamaing, J., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., & Wildiers, H. (2018). Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. Annals of Oncology. doi:10.1093/annonc/mdy210

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E., & JERUSALEM, G. (24 February 2018). MT4-MMP, EGFR and RB expressions are predictive biomarkers of response to Erlotinib-Palbociclib combination in TNBC. Paper presented at Belgian Society of Medical Oncology: annual meeting, Ostende, Belgium.

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Marangoni, E., Noël, A., Sounni, N. E., JERUSALEM, G., Coibion, M., Jossa, V., & BLACHER, S. (27 January 2018). Expression of MT4-MMP, EGFR and Rb in triple negative breast cancers strongly sensitizes tumors to Erlotinib and Palbociclib combination therapy. Paper presented at Belgian Association for Cancer Research : Annual Meeting, Liège, Belgium.

Catala, G., Mebis, J., JERUSALEM, G., Verhoeven, D., Awada, A., Bols, A., Somers, L., Van Den Broeck, A., Duhoux, F. P., & Machiels, J.-P. (2018). Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clinica Belgica. doi:10.1080/17843286.2018.1563735

Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J. H., Aebi, S., Jerusalem, G., Neven, P., Hitre, E., Graas, M.-P., Simoncini, E., Kamby, C., Thompson, A., Loibl, S., Gavila, J., Kuroi, K., Marth, C., Muller, B., O'Reilly, S., Di Lauro, V., & Goldhirsch, A. (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 19 (1), 127-138. doi:10.1016/S1470-2045(17)30715-5

Di Leo, A., Jerusalem, G., Torres, R., Verhoeven, D., Pendergrass, K., Malorni, L., Lichfield, J., & Martin, M. (2018). First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast, 38, 144-149. doi:10.1016/j.breast.2017.12.016

Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4

Gennari, A., Sun, Z., Hasler-Strub, U., Colleoni, M., Kennedy, M. J., Von Moos, R., Cortes, J., Vidal, M. J., Hennessy, B., Walshe, J., Amillano Parraga, K., Ribi, K., Bernhard, J., Morales, S. M., Pagani, O., Barbeaux, A., Borstnar, S., Rabaglio-Poretti, M., Maibach, R., & Jerusalem, G. (2018). A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of Oncology, 29, 661-668. doi:10.1093/annonc/mdx772

Jerusalem, G., de Boer, R. H., Hurvitz, S., Yardley, D. A., Kovalenko, E., Ejlertsen, B., Blau, S., Ozguroglu, M., Landherr, L., Ewertz, M., Taran, T., Fan, J., Noel-Baron, F., Louveau, A.-L., & Burris, H. (2018). Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncology, 182262. doi:10.1001/jamaoncol.2018.2262

Latge, G., Poulet, C., Bours, V., JOSSE, C., & Jerusalem, G. (2018). Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. International Journal of Molecular Sciences, 19 (1). doi:10.3390/ijms19010123

Plummer, R., Verheul, H. M., De Vos, F. Y. F. L., Leunen, K., Molife, L. R., Rolfo, C., Grundtvig-Sørensen, P., De Grève, J., Rottey, S., JERUSALEM, G., Italiano, A., Spicer, J., Dirix, L., Goessl, C., Birkett, J., Spencer, S., Learoyd, M., Bailey, C., & Dean, E. (2018). Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Advances in Therapy, 35 (11), 1945-1964. doi:10.1007/s12325-018-0804-z

Schroyen, S.* , Adam, S.* , Marquet, M., Jerusalem, G., Thiel, S., Giraudet, A.-L., & Missotten, P. (2018). Communication of healthcare professionals: is there ageism? European Journal of Cancer Care, 27 (1), 12780. doi:10.1111/ecc.12780

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Pivot, X., Vidam, G., Wang, Y., Rodriguez Lorenc, K., Miller, M., & Jerusalem, G. (2018). Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 2018789909. doi:10.1200/JCO.2018.78.9909

Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., JERUSALEM, G., Bartsch, R., Rabaglio-Poretti, M., Kammler, R., Maibach, R., Smyth, M., Di Leo, A., Colleoni, M., Viale, G., Regan, M., & André, F. (December 2017). Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Paper presented at SABCS, San Antonio, United States.

Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J. H., Aebi, S., JERUSALEM, G., Neven, P., Di Lauro, V., Gomez, H., Ruhstaller, T., Abdi, E., Di Leo, A., Müller, B., Maibach, R., Gelber, R., Goldhirsch, A., Coates, A., Regan, M., & Bernhard, J. (December 2017). Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-05 SOLE) : impact on quality of life. Poster session presented at SABCS, San Antonio, United States.

Ribi, K., Sun, Z., JERUSALEM, G., Hasler, U., Colleoni, M., von Moos, R., Cortés, J., Vidal, M., Hennessey, B., Walshe, J., Amillano Parraga, K., Morales Murillo, S., Pagani, O., Barbeaux, A., Borstnar, S., Maibach, R., Regan, M., Gennari, A., & Bernhard, J. (December 2017). Nab-Paclitaxel-based therapy in the first line treatment of metastatic breast cancer (IBCSG 42-12/BIG 2-12 SNAP) : impact of different schedules on quality of life. Poster session presented at SABCS, San Antonio, United States.

Grégoire, C., Bragard, I., Etienne, A.-M., JERUSALEM, G., COUCKE, P., Dupuis, G., Lanctôt, D., & FAYMONVILLE, M.-E. (14 November 2017). Group interventions to reduce emotional distress and fatigue in breast cancer patients. Paper presented at Journée doctorale en santé publique, Bruxelles, Belgium.

Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Bragard, I., Charland-Verville, V., & VANHAUDENHUYSE, A. (November 2017). Intérêt et utilisation de l’hypnose pour améliorer le bien-être physique et psychologique en oncologie. HEGEL: Penser par Soi-Même, 7 (4), 267-275. doi:10.4267/2042/63778

FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264.

Leclerc, A.-F., Foidart-Dessalle, M., Tomasella, M., Coucke, P., DEVOS, M., Bruyère, O., Bury, T., Deflandre, D., Jerusalem, G., LIFRANGE, E., KAUX, J.-F., Crielaard, J.-M., & Maquet, D. (October 2017). Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. European Journal of Physical and Rehabilitation Medicine, 53 (5), 633-642. doi:10.23736/S1973-9087.17.04551-8

Grégoire, C.* , Bragard, I.* , JERUSALEM, G., Etienne, A.-M., COUCKE, P., Dupuis, G., Lanctôt, D., & FAYMONVILLE, M.-E. (19 September 2017). Group interventions to reduce emotional distress and fatigue in breast cancer patients: A nine-month follow-up pragmatic trial. British Journal of Cancer, 10 (117), 1442-1449. doi:10.1038/bjc.2017.326

Schroyen, S.* , Missotten, P.* , Jerusalem, G., Van den Akker, M., Buntinx, F., & Adam, S. (02 September 2017). Association between self-perception of aging, view of cancer and health of older patients in oncology: A one-year longitudinal study. BMC Cancer, 17 (614). doi:10.1186/s12885-017-3607-8

Leclerc, A.-F., KAUX, J.-F., Crielaard, J.-M., Foidart-Dessalle, M., BURY, T., Deflandre, D., COUCKE, P., LIFRANGE, E., DEVOS, M., JERUSALEM, G., & Maquet, D. (18 July 2017). Influence of a multidisciplinary post-breast cancer rehabilitation program on lifestyle and behavior faced with physical activities. Poster session presented at 19th Euro Congress on Cancer Science and Therapy, Lisbonne, Portugal.

Grégoire, C., Bragard, I., VANHAUDENHUYSE, A., Charland-Verville, V., Etienne, A.-M., JERUSALEM, G., & FAYMONVILLE, M.-E. (19 May 2017). Effets d'une intervention basée sur l'hypnose sur la fatigue et la détresse de patients atteints d'un cancer : une étude contrôlée randomisée. Poster session presented at Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège.

Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Etienne, A.-M., COUCKE, P., Dupuis, G., Lanctôt, D., & Bragard, I. (19 May 2017). Etude des effets à long terme de différentes interventions de groupe pour améliorer la détresse émotionnelle et la fatigue chez des patientes atteintes d’un cancer du sein. Poster session presented at Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège.

Wenric, S., El Guendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., Olivier, F., Jossa, V., JERUSALEM, G., JOSSE, C., & BOURS, V. (May 2017). Transcriptome wide analysis of natural antisense transcripts shows potential role in breast cancer. Poster session presented at 50th meeting of the European Society of Human Genetics, Copenhagen, Denmark.

Schroyen, S., Marquet, M., Jerusalem, G., Dardenne, B., Van den Akker, M., Buntinx, F., Adam, S.* , & Missotten, P.*. (31 January 2017). The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study. Journal of Geriatric Oncology, 8 (1), 64-68. doi:10.1016/j.jgo.2016.09.001

BRAGARD, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., LIFRANGE, E., SCHROEDER, H., Wagener, A., Dupuis, G., & Jerusalem, G. (2017). A non-randomized comparison study of self-hypnosis, yoga and cognitive behavioral therapy to reduce emotional distress in breast cancer patients. International Journal of Clinical and Experimental Hypnosis, 65 (2), 189-209. doi:10.1080/00207144.2017.1276363

Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., Emens, L. A., Hrinczenko, B., Edenfield, W., Gurtler, J., von Heydebreck, A., Grote, H. J., Chin, K., & Hamilton, E. P. (2017). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment. doi:10.1007/s10549-017-4537-5

Lancellotti, P., Galderisi, M., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Lestuzzi, C., Santoro, C., MOONEN, M., Jerusalem, G., Andarala, M., & Anker, S. D. (2017). Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure, 4 (3), 312-318. doi:10.1002/ehf2.12162

Noguchi, S., Shinohara, N., Ito, T., Ohtsu, A., Ravaux, A., JERUSALEM, G., Ohno, N., Gallo, J., Bouillaud, E., Fan, J., & Nonomura, N. (2017). Relationship between pulmonary adverse events and everolimus exposure in japanese and non-japanese patients : a meta-analysis of oncology trials. Oncology, 92 (5), 243-254. doi:10.1159/000457904

Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H. S., Jerusalem, G., Urban, P., Robinson, D., Mouhaer, S. L., Tomaso, E. D., Massacesi, C., & Saura, C. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. doi:10.1007/s10549-017-4596-7

Wenric, S., ElGuendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., OLIVIER, F., Jossa, V., Jerusalem, G., JOSSE, C., & Bours, V. (2017). Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Scientific Reports, 7 (1), 17452. doi:10.1038/s41598-017-17811-2

Yip, C., Foidart, P., Somja, J., Truong, A., Lienard, M., Feyereisen, E., SCHROEDER, H., GOFFLOT, S., Donneau, A.-F., COLLIGNON, J., Delvenne, P., Sounni, N. E., Jerusalem, G., & Noël, A. (2017). MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British Journal of Cancer. doi:10.1038/bjc.2017.23

Leclerc, A.-F., JERUSALEM, G., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (December 2016). Multidisciplinary management of breast cancer. Archives of Public Health, 74, 50. doi:10.1186/s13690-016-0163-7

Leclerc, A.-F., Foidart-Dessalle, M., BURY, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (2016). Influence d'un programme de revalidation multidisciplinaire post-cancer du sein sur la fonction physique. In 9ème Congrès commun SFMES - SFTS : Abstract book (pp. 43).

FRERES, P., LOUSBERG, L., & JERUSALEM, G. (July 2016). Cyclin-dependent protein kinase inhibitors in breast cancer treatment. Belgian Journal of Medical Oncology, 10 (4), 132-138.

Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., & Conte, P. (2016). Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm, Expanded-Access Multicenter Trial (BALLET). Annals of Oncology. doi:10.1093/annonc/mdw249

Andre, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O'Regan, R., Isaacs, C., Toi, M., Burris, H., He, W., Robinson, D., Riester, M., Taran, T., Chen, D., & Slamon, D. (20 June 2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 34 (18), 2115-24. doi:10.1200/JCO.2015.63.9161

Kelly, K., Patel, M., Infante, J. R., Iannotti, N., Nikolinakos, P., Leach, J., Wang, D., Chandler, J., JERUSALEM, G., Gurtler, J., Arkenau, H.-T., Bajars, M., von Heydebreck, A., Speit, I., Heery, C., & Gulley, J. L. (April 2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Paper presented at American Association for Cancer Research Annual Meeting, New Orleans, United States.

Schroyen, S., Adam, S., Marquet, M., Jerusalem, G., Thiel, S., Giraudet, A.-L., & Missotten, P. (11 March 2016). Ageism and communication in oncology. Poster session presented at Official 10th European Breast Cancer Conference (EBCC-10).

Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., Jerusalem, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2016). Corrigendum to "Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicenter prospective study" [J. Geriatr. Oncol. 6 (2015) 401-410]. Journal of Geriatric Oncology, 7 (2), 142-3. doi:10.1016/j.jgo.2016.01.005

Bourcy, M., Suarez-Carmona, M., Lambert, J., Francart, M.-E., SCHROEDER, H., Delierneux, C., Skrypek, N., Thompson, E. W., JERUSALEM, G., Berx, G., Thiry, M., Blacher, S., Hollier, B. G., Noël, A., Oury, C., Polette, M., & Gilles, C. (2016). Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells. Cancer Research, 76 (14), 4270-4282.

Bourcy, M., Suarez-Carmona, M., Lambert, J., Francart, M.-E., SCHROEDER, H., Delierneux, C., Thompson, E., Jerusalem, G., Blacher, S., Noël, A., Oury, C., Polette, M., & Gilles, C. (January 2016). Epithelial-mesenchymal transition induces tissue factor and pro-coagulant properties supporting early metastasis of circulating tumor cells. Poster session presented at GIGA-Day 2016, Belgium.

Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., & Jerusalem, G. (2016). Etude pilote auprès de patientes atteintes d'un cancer du sein: Apport des méthodes alternatives. In A.-M. Etienne & I. Bragard, Evolutions Sociales, Innovations et Politiques: nouvelles questions et nouveaux enjeux pour la psychologie de la santé (pp. 51-54). Lyon, France: Editions des Archives Contemporaines.

COLLIGNON, J., LOUSBERG, L., SCHROEDER, H., & JERUSALEM, G. (2016). Triple-negative breast cancer : treatment challenges and solutions. Breast Cancer, 8, 93-107. doi:10.2147/BCTT.S69488

Dirix, L., Swaisland, H., Verheul, H. M. W., Rottey, S., Leunen, K., Jerusalem, G., Rolfo, C., Nielsen, D., Molife, L. R., Kristeleit, R., de Vos-Geelen, Mau-Sorensen, M., Soetekouw, P., van Herpen, C., Fielding, A., So, K., Bannister, W., & Plummer, R. (2016). Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies. Clinical Therapeutics, 38 (10), 2286-2299. doi:10.1016/j.clinthera.2016.08.010

Earley, A., Caceres, V., Burnett, H., Higuchi, K., Wang, J., & JERUSALEM, G. (2016). Impact of chemotherapy (CT) on symptoms and health-related quality of life (HRQOL) in patients (pts) with advanced breast cancer (ABC) : A systematic review. Paper presented at Miami Breast Cancer Conference, Miami, United States.

Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K. L., Esteva, F. J., Chia, S. K. L., Germa, C., Tang, Z., Dhuria, S. V., & Slamon, D. J. (2016). Phase III study of Ribociclib (LEE011) plus Fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have received no or only one line of prior endocrine treatment : MONALEESA-3. Journal of Clinical Oncology, 34, 624.

Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K., Esteva, F. J., Germa, C., Tang, Z., Dhuria, S., & Slamon, D. J. (2016). MONALEESA-3 : A phase III study of Ribociclib (LEE011) with Fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in postmenopausal women who have received no or only one line of prior endocrine therapy. Paper presented at Miami Breast Cancer Conference, Miami, United States.

Fasching, P. A., JERUSALEM, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K., Esteva, F. J., Paquet-Luzy, T., Tang, Z., Lorenc, K. R., & Slamon, D. J. (2016). Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3. Clinical Cancer Research, 2-01-02.

FRERES, P., PONCIN, A., MOONEN, M., Josse, C., Oury, C., BOURS, V., LANCELLOTTI, P., & JERUSALEM, G. (2016). La cardiotoxicité des traitements anti-cancéreux. Revue Médicale de Liège, 71 (9), 382-387.

GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454.

Kenis, C., Heeren, P., Decoster, L., Van Puyvelde, K., Conings, G., Cornelis, F., Cornette, P., Moor, R., Luce, S., Libert, Y., Van Rijswijk, R., Jerusalem, G., Rasschaert, M., Langenaeken, C., Baitar, A., Specenier, P., Geboers, K., Vandenborre, K., Debruyne, P. R., & Wildiers, H. (2016). A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators. Journal of Nutrition, Health and Aging, 20 (1), 60-70. doi:10.1007/s12603-016-0677-2

Lancellotti, P., Moonen, M., & Jerusalem, G. (2016). Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging. Echocardiography, 33 (4), 504-9. doi:10.1111/echo.13187

LOUSBERG, L., COLLIGNON, J., & Jerusalem, G. (2016). Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Therapeutic Advances in Medical Oncology, 8 (6), 429-449. doi:10.1177/1758834016665077

Lousberg, L., & Jerusalem, G. (2016). Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 10, 239-252. doi:10.4137/BCBCR.S12443

MOONEN, M., Frere, P., Lancellotti, P., & Jerusalem, G. (2016). Cardiac Monitoring During Clinical Trials. In Anticancer Treatments and Cardiotoxicity 1st Edition Mechanisms, Diagnostic and Therapeutic Interventions (pp. 387-399). Elsevier Inc. doi:10.1016/B978-0-12-802509-3.00039-X

Neven, P., Generali, D., Ciruelos, E. M., Lang, I., Gavila, J., Bighin, C., Borms, M., Conte, P., Montemurro, F., Sartori, D., Marini, L., Camozzi, M., Lorizzo, K., Ocak, O., & JERUSALEM, G. (2016). Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety from BALLET (CRAD001YIC04). Paper presented at Miami Breast Cancer Conference, Miami, United States.

Neven, P., Generali, D., Ciruelos, E. M., Lang, I., Gavila, J., Bighin, C., Borms, M., Conte, P., Montemurro, F., Sartori, D., Marini, L., Camozzi, M., Lorizzo, K., Ocak, O., & JERUSALEM, G. (2016). Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety form BALLET (CRAD001YIC04). Paper presented at Miami Breast Cancer Conference, Miami, United States.

Plummer, R., Verheul, H. M., Langenberg, M., Leunen, K., Molife, L. R., Rolfo, C., Grundtvig-Soerensen, P., De Greve, J., Rottey, S., JERUSALEM, G., Itiliano, A., Spicer, J., Dirix, L., Goessl, C., Birkett, J., Spencer, S., Learoyd, M., & Dean, E. (2016). Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole or letrozole : Phase I study. Journal of Clinical Oncology, 34, 2562.

Schroyen, S., Missotten, P., Jerusalem, G., GILLES, C., & Adam, S. (2016). Ageism and caring attitudes among nurses in oncology. International Psychogeriatrics, 28 (5), 749-757. doi:10.1017/S1041610215001970

Schroyen, S., Missotten, P., Jerusalem, G., GILLES, C., & Adam, S. (2016). Ageism among nurses in oncology. International Psychogeriatrics. doi:10.1017/S1041610215001970

Verschraegen, C., Chen, F. L., Spigel, D. R., Iannotti, N., McClay, E., Redfern, C. H., Bennouna, J., Taylor, M., Kaufman, H., Kelly, K., Bajars, M., von Heydebreck, A., Cuillerot, J.-M., & JERUSALEM, G. (2016). Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression. Journal of Clinical Oncology, 34, 9036.

Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786

Francart, M.-E., Bourcy, M., Lambert, J., Suarez-Carmona, M., Jerusalem, G., Oury, C., Noël, A., & Gilles, C. (03 December 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression. Poster session presented at Télévie's researchers seminar, Gembloux, Belgium.

Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (03 December 2015). MT4-MMP, a potential prognostic factor in triple negative breast cancer. Paper presented at Séminaire des chercheurs Télévie 2016, Gembloux, Belgium.

Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (14 October 2015). Ageism among nurses in oncology. Poster session presented at IPA International Congress, Berlin, Germany.

Leclerc, A.-F., FOIDART-DESSALLE, M., Bury, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (2015). Psychological benefits of a multidisciplinary rehabilitation program after breast cancer. In European Cancer Congress : Abstract book.

Leclerc, A.-F., FOIDART-DESSALLE, M., Bury, T., Deflandre, D., COUCKE, P., JERUSALEM, G., LIFRANGE, E., DEVOS, M., CRIELAARD, J.-M., & Maquet, D. (26 September 2015). Physical benefits of a multidisciplinary rehabilitation program after breast cancer. Poster session presented at European Cancer Congress, Vienne, Austria.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., Jerusalem, G., Sounni, N. E., & Noël, A. (11 September 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at EDT-Cancérologie Expérimentale Annual symposium « New advances in animal models in cancerology ».

Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (September 2015). MT4-MMP, a potential therapeutic target in triple negative breast cancer. Poster session presented at 2nd international society of cancer metabolism meeting - METABOLISM and MICROENVIRONMENT in CANCER PLASTICITY, Venise, Italy.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (June 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at Biomedica Life Science Summit, Genk, Belgium.

Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (13 May 2015). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread. Paper presented at GIGA-Cancer Day, Liège, Belgium.

Francart, M.-E., Bourcy, M., Lambert, J., Suarez-Carmona, M., Jerusalem, G., Oury, C., Noël, A., & Gilles, C. (13 May 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression. Poster session presented at GIGA-Cancer-Day, Liège, Belgium.

Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (May 2015). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread. Poster session presented at GIGA-Cancer-Day.

JERUSALEM, G., Mariani, G., Ciruelos Gil, E. M., Martin, M., Tjan-Heijnen, V. C., Neven, P., Gavila Gregori, J., Michelotti, A., Montemurro, F., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Brenski, D., & Conte, P. (May 2015). Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04). Cancer Research, 75 (9), 5-19-02.

Kaufman, P. A., Freyer, G., Kemeny, M., Gonçalves, A., JERUSALEM, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., Pickett, C. A., & Wildiers, H. (May 2015). A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer. Cancer Research, 75 (9), 5-19-14.

Boukerroucha, M., Josse, C., SEGERS, K., El Guendi, S., FRERES, P., JERUSALEM, G., & Bours, V. (26 March 2015). BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer, 15, 181. doi:10.1186/s12885-015-1205-1

Perez Palacios, A., Blomme, A., Boutry, S., Doumont, G., Sherer, F., Van Simaeys, G., Debois, D., JERUSALEM, G., COLLIGNON, J., DELVENNE, P., DETRY, O., De Pauw, E., Muller, R., Goldman, S., Castronovo, V., & Turtoi, A. (March 2015). Metabolomic, proteomic and preclinical imaging of patient-derived tumor xenografts for improving treatment of liver metastases patients. Acta Gastro-Enterologica Belgica, 78 (1), 134.

Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., DELVENNE, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (11 February 2015). Involvement of Epithelial-to-Mesenchymal Transitions on the interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread. Paper presented at Journée Télévie, Brussels, Belgium.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (11 February 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at Séminaire des chercheurs Télévie 2015, Bruxelles, Belgium.

Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Delvenne, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (February 2015). Involvement of Epithelial-to-Mesenchymal Transitions on the interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread. Poster session presented at Télévie's researchers seminar.

NIZET, J.-L., MAWEJA, S., LAKOSI, F., LIFRANGE, E., SCAGNOL, I., SEIDEL, L., Albert, A., & JERUSALEM, G. (February 2015). Oncological and surgical outcome after oncoplastic breast surgery. Acta Chirurgica Belgica, 115, 33-41. doi:10.1080/00015458.2015.11681064

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (31 January 2015). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at ABEC - Tumor Metabolism and Mitochondria, Bruxelles, Belgium.

JERUSALEM, G. (29 January 2015). Do we have to change our anti-cancer strategy in case of cardiac toxicity ? Point of view of the oncologist. Paper presented at 34th Annual Congress Belgian Society of Cardiology, Brussels, Belgium.

Francart, M.-E., Bourcy, M., Suarez-Carmona, M., JERUSALEM, G., Oury, C., & Gilles, C. (27 January 2015). Regulation of Tissue Factor by Epithelial-to-Mesenchymal Transitions: Impacts for the metastatic progression. Poster session presented at GIGA Day 2015.

Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., Jerusalem, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2015). Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study. Journal of Geriatric Oncology, 6 (5), 401-10. doi:10.1016/j.jgo.2015.07.005

Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., JERUSALEM, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2015). Implementation of geriatric assessment - based recommendations in older patients with cancer : a multicenter prospective study. Journal of Geriatric Oncology, 6, 13-S27.

Boukerroucha, M., Josse, C., El Guendi, S., Boujemla, B., Freres, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., Jerusalem, G., & Bours, V. (2015). Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer, 15 (1), 755. doi:10.1186/s12885-015-1740-9

Boukerroucha, M., Josse, C., El Guendi, S., FRERES, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., JERUSALEM, G., & BOURS, V. (2015). Genetic study of triple negative breast cancers. Poster session presented at Impakt Breast Cancer Conference, Brussels, Belgium. doi:10.1093/annonc/mdv116.11

Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520

Carnet, O.* , Lecomte, J.* , Masset, A., Primac, I., Durré, T., Maertens, L., Detry, B., Blacher, S., Gilles, C., Péqueux, C., Paupert, J., Foidart, J.-M., Jerusalem, G., Cataldo, D., & Noël, A. (2015). Mesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine manner. Neoplasia, 17 (7), 552-63. doi:10.1016/j.neo.2015.07.002

COLIN, P.-E., SCHROEDER, H., GONNE, E., Hanocq, F., ANDRE, C., RORIVE, A., Jerusalem, G., & COLLIGNON, J. (2015). BIOPSIE DES LESIONS SUSPECTES CHEZ LES PATIENTS AYANT PRESENTE UN CANCER DU SEIN. Revue Médicale de Liège, 70 (11), 563-8.

Damaraju, S., Gorbunova, V., Gelmon, K. A., Garcia Saenz, J. A., Morales, S., Abigerges, D. Y., Canon, J.-L., Lifirenko, I., Cohen, G. L., JERUSALEM, G., Thireau, F., Fresco, R., Houé, V., Press, M. F., Narasimhan, A., & Mackey, J. R. (2015). Relationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial. Journal of Clinical Oncology, (suppl abstr 540).

Dieras, V., Wildiers, H., Jassem, J., Dirix, L. Y., Guastalla, J.-P., Bono, P., Hurvitz, S. A., Goncalves, A., Romieu, G., Limentani, S. A., Jerusalem, G., Lakshmaiah, K. C., Roche, H., Sanchez-Rovira, P., Pienkowski, T., Segui Palmer, M. A., Li, A., Sun, Y.-N., Pickett, C. A., & Slamon, D. J. (2015). Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast, 24, 182-190. doi:10.1016/j.breast.2014.11.003

FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200.

Generali, D., Venturini, S., Rognoni, C., Ciani, O., Pusztai, L., Loi, S., Jerusalem, G., Bottini, A., & Tarricone, R. (2015). A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 152 (1), 95-117. doi:10.1007/s10549-015-3453-9

JERUSALEM, G., COLLIGNON, J., Josse, C., SCHROEDER, H., RORIVE, A., FRERES, P., LAMBERT, F., KOOPMANSCH, B., PONCIN, A., & BOURS, V. (2015). Cancer du sein : de la thérapie ciblée à la médecine personnalisée. Revue Médicale de Liège, 70 (5-6), 269-276.

JERUSALEM, G., MOONEN, M., FRERES, P., & LANCELLOTTI, P. (2015). The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment. Future Oncology, 11 (20), 2791-2794. doi:10.2217/fon.15.227

Jerusalem, G., Neven, P., Marinsek, N., Zhang, J., Degun, R., Benelli, G., Saletan, S., Ricci, J.-F., & Andre, F. (2015). Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer, 15, 787. doi:10.1186/s12885-015-1762-3

Jerusalem, G., RORIVE, A., & COLLIGNON, J. (2015). Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Future Oncology, 11 (12), 1775-89. doi:10.2217/fon.15.80

Kelly, K., Patel, M. R., Infante, J. R., Iannotti, N., Nikolinakos, P., Leach, J., Wang, D., Chandler, J. C., JERUSALEM, G., Gurtler, J. S., Arkenau, H.-T., Speit, I., von Heydebreck, A., CHIN, K. M., Heery, C. R., & Gulley, J. L. (2015). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study. Journal of Clinical Oncology, 33 (suppl ; abstr 3044).

Kenis, C., Flamaing, J., Debruyne, P. R., Rasschaert, M., Focan, C., Cornelis, F., Verschaeve, V., Vanoverbeke, K., Libert, Y., Luce, S., Decoster, L., Nols, N., Van den Bulck, H., Goeminne, J.-C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., & Wildiers, H. (2015). A nationwide implementation of a multidisciplinary geriatric assessment and intervention program in belgian older patients with cancer. Journal of Geriatric Oncology, 6 (S13-S27), 001.

Lancellotti, P., Anker, S. D., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Maggioni, A. P., Jerusalem, G., & Galderisi, M. (2015). EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. European Heart Journal - Cardiovascular Imaging. doi:10.1093/ehjci/jev024

Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcene, A., BIANCHI, E., GOFFLOT, S., Drion, P., Trombino, G. E., Di Valentin, E., CUSUMANO, G., MAWEJA, S., JERUSALEM, G., Delvenne, P., LIFRANGE, E., Castronovo, V., & Turtoi, A. (2015). Asporin Is a Fibroblast-Derived TGF-beta1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS Medicine, 12 (9), 1001871. doi:10.1371/journal.pmed.1001871

Plummer, E. R., Verheul, H. M. W., Rottey, S., Leunen, K., JERUSALEM, G., Rolfo, C. D., Nielsen, D. L., Molife, L. R., Kristeleit, R., de Vos-Geelen, J., Mau-Sorensen, M., Soetekouw, P. M. M. B., van Herpen, C., Swaisland, H., Fielding, A., So, K., Bannister, W., & Dirix, L. (2015). Effect of itraconazole and rifampin on the pharmacokinetics of olaparib table formulation in patients with advanced solid tumors : phase I open-label studies. Journal of Clinical Oncology, 33 (suppl : abstr 2565).

Plummer, R., Swaisland, H., Leunen, K., van Herpen, C. M. L., JERUSALEM, G., De Grève, J., Lolkema, M. P., Soetekouw, P., Mau-Sorensen, M., Nielsen, D., Spicer, J., Fielding, A., So, K., Bannister, W., & Molife, L. R. (2015). Olaparib tablet formulation : effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76, 723-729. doi:10.1007/s00280-015-2836-2

RORIVE, A., EL HAYDERI, L., LIBON, F., DEZFOULIAN, B., JERUSALEM, G., NIKKELS, A., & LEBAS, E. (2015). VISMODEGIB ET CARCINOMES BASOCELLULAIRES LOCALEMENT AVANCES. Revue Médicale de Liège.

SCHROEDER, H., Hanocq, F., COLLIGNON, J., Colin, P.-E., Depuis, Z., Triffaux, F., RORIVE, A., & JERUSALEM, G. (2015). Cancer du sein: intérêt du bilan d’extension par imagerie lors du diagnostic initial et du suivi les trois premières années après le diagnostic. Revue Médicale de Liège, 70 (3), 140-147.

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2015). Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads. Clinical Interventions in Aging, 10, 117-125. doi:10.2147/CIA.S70942

Schroyen, S., Missotten, P., Marquet, M., Clesse, A., Flamion, A., JERUSALEM, G., & Adam, S. (2015). Le regard (peu optimiste) du soignant sur la personne âgée. Medi-Sphere, 469, 1-3.

Slamon, D., Hurvitz, S., Chen, D., Andre, F., Tseng, L.-M., JERUSALEM, G., Wilks, S., O'Regan, R., Isaacs, C., Toi, M., Burris, H., He, W., Riester, M., Robinson, D., Taran, T., & Gianni, L. (2015). Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer : combined exploratory analysis from BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 33 (suppl ; abstr 512).

Slomian, J., LECLERC, A.-F., Maquet, D., JERUSALEM, G., LIFRANGE, E., COUCKE, P., Bury, T., TOMASELLA, M., Reginster, J.-Y., Bruyère, O., & Crielaard, J.-M. (2015). Prevalence of endocrine therapies that could affect bone health in women following a rehabilitation program after surgery for breast cancer. Osteoporosis International, 26 (S1), 375.

Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., Coudert, S., & Jerusalem, G. (16 December 2014). Améliorer le bien-être des patientes atteintes d’un cancer du sein par l’auto-hypnose, le yoga ou la TCC en groupe : faisabilité et premiers résultats au CHU de Liège. Paper presented at 8e congrès de l’Association Francophone de Psychologie de la Santé (AFPSA).

Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (16 December 2014). Personnel soignant et âgisme: quelles conséquences cliniques ? Paper presented at 8e congrès de l'Association Francophone de Psychologie de la Santé, Liège, Belgium.

Gupta, S., Zhang, J., & JERUSALEM, G. (2014). The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer : experience from the patient perspective. Expert Review of Pharmacoeconomics and Outcomes Research. doi:10.1586/14737167.2014.949243

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2014). Double stigmatization influence in oncogeriatry. Psycho-oncology.

Kenis, C., Heeren, P., Bron, D., Decoster, L., Moor, R., Pepersack, T., Langenaeken, C., Rasschaert, M., Jerusalem, G., Van Rijswijk, R., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (01 October 2014). Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations. Journal of Geriatric Oncology, 5 (4), 431-438. doi:10.1016/j.jgo.2014.06.043

Paye, A., Truong, A., Yip, C., Cimino, J., Blacher, S., Munaut, C., Cataldo, D., Foidart, J.-M., Maquoi, E., COLLIGNON, J., Delvenne, P., Jerusalem, G., Noël, A.* , & Sounni, N. E.*. (October 2014). EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP. Cancer Research, 74 (23), 6758-70. doi:10.1158/0008-5472.CAN-13-2994

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (30 September 2014). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at Ecole Doctorale Thematique En Cancerologie Experimentale, Liege, Belgium.

JERUSALEM, G. (19 September 2014). Fertility and pregnancy after adjuvant therapy. Paper presented at Câncer de mama - Gramado 2014 - 9e édition, Gramado, Brazil.

JERUSALEM, G. (19 September 2014). Endocrine therapy resistance. Paper presented at Câncer de mama - Gramado 2014 - 9e édition, Gramado, Brazil.

Schroyen, S., Missotten, P., JERUSALEM, G., GILLES, C., & Adam, S. (18 September 2014). L'âgisme en oncogériatrie. Paper presented at Société francophone d'oncogériatrie.

FRERES, P., JOSSE, C., Bovy, N., Boukerroucha, M., Struman, I., BOURS, V., & JERUSALEM, G. (2014). Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression. Journal of Cellular Physiology. doi:10.1002/jcp.24730

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (June 2014). Impact de la double stigmatisation en oncogériatrie : Etat des lieux. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (2), 131-8. doi:10.1684/pnv.2014.0471

Francart, M.-E., Bourcy, M., Suarez-Carmona, M., JERUSALEM, G., Oury, C., & Gilles, C. (19 May 2014). Implication of Epithelial-to-Mesenchymal Transitions (EMTs) on coagulant properties of Circulating Tumor Cells (CTCs): impacts for the metastatic progression. Poster session presented at GIGA-Cancer Day 2014.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (19 May 2014). Clinical significance of MT4-MMP and EGFR expression in Breast Cancer. Paper presented at GIGA-Cancer Day 2014, Liege, Belgium.

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (15 May 2014). Etude longitudinale en oncogériatrie: impact de la double stigmatisation. Poster session presented at Congrès International francophone de Gérontologie et Gériatrie, Liège, Belgium.

Bourcy, M., Suarez-Carmona, M., Francart, M.-E., Lambert, J., Foidart, J.-M., Delvenne, P., Jerusalem, G., Noël, A., Oury, C., & Gilles, C. (May 2014). Epithelial-to-Mesenchymal Transitions modulate interactions between Circulating Tumor Cells and the coagulation system: implication for the metastatic spread. Poster session presented at GIGA-Cancer-Day.

JERUSALEM, G., Gupta, S., & Zhang, J. (May 2014). The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Value in Health, 17 (3), 95.

JERUSALEM, G. (24 April 2014). Selecting the neoadjuvant treatment by molecular subtype : How to maximize the benefits. Paper presented at IX Santiago International Breast Cancer Symposium, Santiago, Chile.

JERUSALEM, G. (24 April 2014). Mechanisms of endocrine resistance and how to overcome them ? Taking advantage of the cross talk at the clinical level. Paper presented at IX Santiago International Breast Cancer Symposium, Santiago, Chile.

JERUSALEM, G. (24 April 2014). Extended adjuvant endocrine therapy. Who benefits ? For how long ? Paper presented at IX Santiago International Breast Cancer Symposium, Santiago, Chile.

JERUSALEM, G. (21 March 2014). This house believes that 5 or fewer years of adjuvant endocrine therapy is insufficient. Paper presented at 9th European Breast Cancer Conference, Glasgow, United Kingdom.

JERUSALEM, G. (22 February 2014). New chemotherapy drugs in metastatic breast cancer. Paper presented at Innovation in breast cancer - IBC 2014, Madrid, Spain.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (27 January 2014). Study of the pro-tumoral effects of MT4-MMP. Paper presented at GIGA-Day 2014, Liege, Belgium.

Andre, F., Neven, P., Marinsek, N., Zhang, J., Baladi, J.-F., Degun, R., Benelli, G., Saletan, S., & Jerusalem, G. (2014). Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Current Medical Research and Opinion. doi:10.1185/03007995.2014.887002

Andre, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., Yap, Y.-S., Papai, Z., Lang, I., Armstrong, A., Lerzo, G., White, M., Shen, K., Litton, J., Chen, D., & Gianni, L. (2014). Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology. doi:10.1016/S1470-2045(14)70138-X

BARTHELEMY, N., GENNIGENS, C., Scholtes, F., TSHIBANDA, L., OTTO, B., PIRET, P., MARTIN, D., JERUSALEM, G., & COUCKE, P. (2014). Le traitement multidisciplinaire du glioblastome. Revue Médicale de Liège, 69, 63-68.

BARTHELEMY, N., LENNERTS, E., MEYNS, M., DUYSINX, B., PAULUS, A., COMPERE, C., BOSQUEE, L., JERUSALEM, G., & COUCKE, P. (2014). LE DÉFI DU CONTRÔLE LOCAL DANS LE CANCER PULMONAIRE NON A PETITES CELLULES, LOCALEMENT AVANCE, NON OPERABLE. Revue Médicale de Liège, 69 (Supp 1), 75-80.

Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C. G. M., Slaets, L., & Cameron, D. (2014). Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Annals of Oncology. doi:10.1093/annonc/mdu551

Bragard, I., Etienne, A.-M., Faymonville, M.-E., Coucke, P., DEVOS, M., LIFRANGE, E., SCHROEDER, H., Wagener, A., & Jerusalem, G. (2014). Self-hypnosis, yoga or CBT group to face breast cancer: feasibility study and first results in Belgium. Psycho-oncology, 23 (suppl 3), 174.

Coleman, R., Aksnes, A.-K., Naume, B., Garcia, C., Jerusalem, G., Piccart, M., Vobecky, N., Thuresson, M., & Flamen, P. (2014). A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment. doi:10.1007/s10549-014-2939-1

Cusumano, P. G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., LIFRANGE, E., Jerusalem, G., Klaase, J., de Snoo, F., Stork-Sloots, L., Dekker-Vroling, L., & Lutke Holzik, M. (2014). European inter-institutional impact study of MammaPrint. Breast, 23 (4), 423-8. doi:10.1016/j.breast.2014.02.011

Duray, A., Demoulin, S., Petermans, J., Moutschen, M., Saussez, S., Jerusalem, G., & Delvenne, P. (2014). Vieillissement et cancer: coincidence ou relation etiologique? Revue Médicale de Liège, 69 (5-6), 276-81.

Jerusalem, G., Bachelot, T., Barrios, C., Neven, P., Di Leo, A., Janni, W., & de Boer, R. (2014). A new era of improving progression-free survival with dual blockade in postmenopausal HR, HER2 advanced breast cancer. Cancer Treatment Reviews. doi:10.1016/j.ctrv.2014.12.011

JERUSALEM, G., Gupta, S., & Zhang, J. (2014). The association of chemotherapy versus hormonal therapy and health outcomes by geographic region among patients with hormone receptor-positive, HER2-negative metastatic breast cancer : experience from the patient perspective. Poster session presented at 9th European Breast Cancer Conference, Glasgow, United Kingdom.

Jerusalem, G., RORIVE, A., & COLLIGNON, J. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer, 6, 43-57. doi:10.2147/BCTT.S38679

JERUSALEM, G., RORIVE, A., & COLLIGNON, J. (2014). Le médicament du mois : Everolimus (Afinitor) dans le traitement du cancer du sein métastatique. Revue Médicale de Liège, 69 (9), 510-517.

Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Malorni, L., Garnett, S., Rukazenkov, Y., & Martin, M. (2014). Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 106 (1), 337. doi:10.1093/jnci/djt337

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., & Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging, 15 (10), 1063-93. doi:10.1093/ehjci/jeu192

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., & Lancellotti, P. (2014). Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27 (9), 911-39. doi:10.1016/j.echo.2014.07.012

Saura, C., Bendell, J., Jerusalem, G., Su, S., Ru, Q., De Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., Beck, J. T., Di Tomaso, E., Sternberg, D. W., Massacesi, C., Hirawat, S., Dirix, L., & Baselga, J. (2014). Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clinical Cancer Research, 20 (7), 1935-45. doi:10.1158/1078-0432.CCR-13-1070

Schroyen, S., Adam, S., Jerusalem, G., & Missotten, P. (2014). L'âgisme et ses conséquences cliniques en oncogériatrie: état des lieux et pistes d'interventions. Revue Médicale de Liège, 69 (5-6), 395-401.

Wenric, S., Freres, P., Josse, C., Bours, V., & Jerusalem, G. (09 December 2013). A miRNA expression based diagnostic tool for breast cancer using random forests. Poster session presented at Benelux Bioinformatics Conference 2013.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., Jerusalem, G., Sounni, N. E., & Noël, A. (05 December 2013). Study of the pro-tumoral effects of MT4-MMP. Paper presented at Séminaire des chercheurs Télévie 2014, Bruxelles, Belgium.

Gennari, A., JERUSALEM, G., & Maibach, R. (December 2013). The SNAP trial : schedules of nab-Paclitaxel in metastatic breast cancer. International breast cancer study group (ICGSG 42-12) and breast international group (BIG 2-12). Cancer Research, 73 (24), 3-1-02.

Isaacs, C., Ozguroglu, M., JERUSALEM, G., Xu, B., Lang, I., O'Regan, R., White, M., Fasolo, A., Litton, J., Toi, M., Shen, K., André, F., Vuylsteke, P., Zhang, Y., Zhang, J., Taran, T., & Wilks, S. (December 2013). BOLERO-3 : Quality-of-life maintained in patients with HER-2 positive metastatic breast cancer treated with Everolimus plus Trastuzumab plus Vinorelbine. Cancer Research, 73 (24), 4-12-18.

JERUSALEM, G., Masuda, N., Andre, F., Fein, L., Fasolo, A., O'Regan, R., Wilks, S., Isaacs, C., Zhang, Y., Taran, T., & Toi, M. (December 2013). Safety analysis of BOLERO-3 : a phase III trial of daily Everolimus vs placebo, both with weekly Trastuzumab and Vinorelbine in Trastuzumab-resistant, advanced breast cancer. Cancer Research, 73 (24), 3-15-03.

Toi, M., Masuda, N., ANDRE, F., Ishiguro, H., Fasolo, A., Xu, B., JERUSALEM, G., Shen, K., Wilks, S., O'Regan, R., Isaacs, C., Zhang, Y., Taran, T., & Yap, Y.-S. (December 2013). BOLERO-3 : Everolimus plus Trastuzumab and Vinorelbine in asian patients with HER2-positive metastatic breast cancer. Cancer Research, 73 (24), 4-12-19.

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (16 November 2013). Etude longitudinale en oncogériatrie: impact de la double stigmatisation. Poster session presented at 40 èmes Journées Scientifiques de l'Association pour l'Etude, la Modification et la Thérapie du Comportement, Liège, Belgium.

de Boer, R., JERUSALEM, G., Hurvitz, S., Ejlertsen, B., El-Hashimy, M., Feng, W., Taran, T., & Burris, H. (November 2013). Efficacy and safety of Everolimus plus Exemestane combinaison therapy versus monotherapy with Everolimus or Capecitabine in HR+, HER2- breast cancer : a multicenter, open-label, phase 2 trial BOLERO-6. Breast, 22 (3).

Martin, L.-A., Andre, F., Campone, M., Bachelot, T., & JERUSALEM, G. (November 2013). mTOR inhibitors in advanced breast cancer: ready for prime time? Cancer Treatment Reviews, 39 (7), 742-52. doi:10.1016/j.ctrv.2013.02.005

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (13 September 2013). Study of the pro-tumoral effects of MT4-MMP. Paper presented at Annual Mini Symposium 2013, Liege, Belgium.

JERUSALEM, G., ANDRE, F., CHEN, D., ROBINSON, D., OZGUROGLU, M., LANG, I., WHITE, M., TOI, M., TARAN, T., & GIANNI, L. (September 2013). Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial. European Journal of Cancer, 49 (Supplement 3), 8.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (02 July 2013). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at Mini symposium "Tumor Microenvironment", Liege, Belgium.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (17 May 2013). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at GIGA-Cancer Day 2013.

Wenric, S., JOSSE, C., Fasquelle, C., Poulet, C., Sticca, T., Boukerroucha, M., JERUSALEM, G., & Bours, V. (15 March 2013). Exome sequencing of tumors: relevance in copy-number alteration (CNA) analysis and fixed tissue samples. Poster session presented at 13th Annual Meeting of the Belgian Society of Human Genetics, Bruxelles, Belgium.

Ejlertsen, B., JERUSALEM, G., Hurvitz, S., de Boer, R., Taran, T., Sahmoud, T., & Burris, H. (March 2013). Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6. Poster session presented at St. Gallen International Breast Cancer Conference, St Gallen, Switzerland.

Vanderhaegen, J., Paridaens, R., Piccart, M., Lalami, Y., Machiels, J., JERUSALEM, G., Borms, M., Goeminne, J., Mebis, J., Dirix, L., De Greve, J., Berteloot, P., Lintermans, A., Brouckaert, O., & Neven, P. (March 2013). The 2006 adjuvant Trastuzumab convention in Belgium: 5 years later. Poster session presented at 13th St Gallen International Breast Cancer Conference 2013, Saint-Gallen, Switzerland.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (29 January 2013). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at GIGA-Day 2013, Liege, Belgium.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (29 January 2013). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at EDT cancérologie.

Awada, A., Garcia, A. A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncology, 14 (12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7

Bachelot, T., McCool, R., Duffy, S., Glanville, J., Varley, D., Fleetwood, K., Zhang, J., & Jerusalem, G. (2013). Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Research and Treatment. doi:10.1007/s10549-013-2778-5

Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61.

Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J.-C., Viguier, M., Cocquyt, V., JERUSALEM, G., Machiels, J.-P., Prenen, H., Masson, P., Louis, E., & De Keyser, F. (2013). Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 12 (1), 98. doi:10.1186/1476-4598-12-98

Ejlerstsen, B., JERUSALEM, G., Hurvitz, S., de Boer, R., Taran, T., Sahmoud, T., & Burris, H. (2013). Bolero-6:Phase 2 Study of Everolimus plus Exemestane versus Everolimus or Capecitabine Monotherapy in HR+HER2- Advanced Breast Cancer. Journal of Clinical Oncology, 31, 660.

Flamen, P., Coleman, R., Naume, B., JERUSALEM, G., Garcia, C., Aksnes, A.-K., & Piccart, M. (2013). 18F-FDG PET : Changes in uptake as a method to assess radium-223 dichloride (Ra-223) response in bone metastases of breast cancer patients with bone-dominant disease. Journal of Nuclear Medicine, 54 (supplement 2), 647.

Garnett, S. A., Martin, M., JERUSALEM, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Lindemann, J. P. O., & Di Leo, A. (2013). Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 138 (1), 149-55. doi:10.1007/s10549-012-2395-8

Senkus, E., Gomez, H., Dirix, L., JERUSALEM, G., Murray, E., Van Tienhoven, G., Westenberg, A. H., Bottomley, A., Rapion, J., Bogaerts, J., Di Leo, A., & Neskovic-Konstantinovic, Z. (2013). Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psycho-oncology. doi:10.1002/pon.3384

DI LEO, A., JERUSALEM, G., PETRUZELKA, L., TORRES, R., BONDARENKO, I. N., KHASANOV, R., VERHOEVEN, D., PEDRINI, J. L., SMIRNOVA, I., LICHINITSER, M. R., PENDERGRASS, K., GARNETT, S., RUKAZENKOV, Y., & MARTIN, M. (15 December 2012). Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Research. Supplement, 72 (24), 1-4.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (10 December 2012). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at Séminaire des chercheurs Télévie 2013, Liege, Belgium.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (09 November 2012). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at Fall meeting of the belgian society for biochemistry and molecular biology - "Metabolomics... To Do What?", Namur, Belgium.

ANDRE, F., MARINSEK, N., RICCI, J.-F., ETCHBERGER, J., DEGUN, R., BENELLI, G., SALETAN, S., & JERUSALEM, G. (November 2012). Patterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe. Value in Health, 15 (7), 419.

Marchal, N., GENNIGENS, C., & JERUSALEM, G. (November 2012). Carcinomatose péritonéale d'origine indéterminée. Revue Médicale de Liège, 67 (11), 582-586.

Yip, C., PAYE, A., Truong, A., Cimino, J., COLLIGNON, J., DELVENNE, P., JERUSALEM, G., Sounni, N. E., & Noël, A. (13 October 2012). Regulation of breast cancer cell properties by MT4-MMP. Paper presented at Fall meeting of the belgian society for cell and developmental biology - epidermal cell biology, Namur, Belgium.

COLLIGNON, J., & JERUSALEM, G. (2012). Les traitements cibles remplaceront-ils la chimiotherapie? Revue Médicale de Liège, 67 Spec No, 29-36.

Coudert, B., Asselain, B., Campone, M., Spielmann, M., Machiels, J.-P., Penault-Llorca, F., Serin, D., Levy, C., Romieu, G., Canon, J.-L., Orfeuvre, H., Piot, G., Petit, T., JERUSALEM, G., Audhuy, B., Veyret, C., Beauduin, M., Eymard, J.-C., Martin, A.-L., & Roche, H. (2012). Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. Oncologist, 17 (7), 900-909. doi:10.1634/theoncologist.2011-0442

CUSUMANO, G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., LIFRANGE, E., JERUSALEM, G., Klaase, J., Stork-Sloots, L., & Lutke Holzik, M. (2012). European inter-institutional impact study of MammaPrint. Poster session presented at ESMO 2012 Congress Vienna, Vienna, Austria.

GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42.

JERUSALEM, G., MARINSEK, N., RICCI, J.-F., ETCHBERGER, J., DEGUN, R., BENELLI, G., SALETAN, S., & ANDRE, F. (2012). Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe. Poster session presented at 2012 ESMO congress, Vienne, Austria.

Llombart, A., Frassoldati, A., Paija, O., Sleeboom, H. P., JERUSALEM, G., Mebis, J., Deleu, I., Miller, J., Schenk, N., & Neven, P. (2012). Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clinical Breast Cancer, 12 (1), 40-8.

Pistilli, B., Urruticoechea, A., Chan Stephen, Han, H. S., JERUSALEM, G., Kong, A., Ru, Q., Ruquet, S., Sternberg, D., & Saura, C. (2012). Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer. Annals of Oncology, 23 (supplément 9), 116.

VANDERHAEGEN, J., PARIDAENS, R., PICCART, M., LALAMI, Y., Machiels, J., JERUSALEM, G., BORMS, M., GOEMINNE, J., MEBIS, J., DIRIX, L., LINTERMANS, A., BROUCKAERT, O., & NEVEN, P. (2012). The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later. Cancer Research, 5-18-19.

ANDRE, C., COLLIGNON, J., RORIVE, A., MARTIN, M., MAWEJA, S., LIFRANGE, E., COUCKE, P., & JERUSALEM, G. (2011). Le cancer du sein chez la femme jeune. Revue Médicale de Liège, 66 (5-6), 397-399.

Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Brown, M., Zhao, C., Hannah, A. L., Masuoka, L. K., Garcia, A., & Perez, E. A. (2011). Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). Journal of Clinical Oncology, 29.

COLLIGNON, J., RORIVE, A., MARTIN, M., ANDRE, C., MAWEJA, S., LIFRANGE, E., COUCKE, P., & JERUSALEM, G. (2011). Chimiothérapie et cancer du sein. Revue Médicale de Liège, 66 (5-6), 372-378.

COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396.

COUCKE, P., JANSEN, N., JANVARY, Z. L., LOUIS, C., VANDERICK, J., RORIVE, A., COLLIGNON, J., LIFRANGE, E., MAWEJA, S., & JERUSALEM, G. (2011). Accelerated partial breast irradiation: state of the art. Belgian Journal of Medical Oncology, 5 (1), 3-7.

COUCKE, P., LAKOSI, F., RORIVE, A., JANVARY, Z. L., COLLIGNON, J., JANSEN, N., ANDRE, C., & JERUSALEM, G. (2011). Radiothérapie et cancer du sein : "standards" de traitement, prédiction de rechute locale et questions ouvertes. Revue Médicale de Liège, 66 (5-6), 320-325.

Dieras, V., Jassem, J., Dirix, L. Y., Guastalla, J. P., Bono, P., Hurvitz, S. A., Gonçalves, A., Romieu, G., Limentani, S. A., JERUSALEM, G., Lakshmaiah, K., Roche, H. H., Sanchez-Rovira, P., Pienkowski, T., Segui-Palmer, M. A., Li, A., Sun, Y., Pickett-Gies, C. A., & Wildiers, H. (2011). A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). Journal of Clinical Oncology, 29.

Garcia, A., Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Brown, M., Zhao, C., Hannah, A. L., Leung, A. C. F., Masuoka, L. K., & Perez, E. A. (2011). Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. Journal of Clinical Oncology, 29 (supplement 27).

GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5.

Gilles, C., COLLIGNON, J., Noël, A., Jerusalem, G., & Foidart, J.-M. (2011). Cellules Tumorales Circulantes : détection, caractérisation et intérêts cliniques. Revue Médicale de Liège, 66 (5-6), 279-84.

JERUSALEM, G., COLLIGNON, J., RORIVE, A., LIFRANGE, E., ANDRE, C., MARTIN, M., MAWEJA, S., & COUCKE, P. (2011). Traitements ciblés dans le cancer du sein. Revue Médicale de Liège, 66 (5-6), 379-384.

JERUSALEM, G., & COUCKE, P. (2011). Apport de la consultation oncologique multidisciplinaire dans le choix des options thérapeutiques. Revue Médicale de Liège, 66 (5-6), 311-314.

Jerusalem, G., Fasolo, A., Dieras, V., Cardoso, F., Bergh, J., Vittori, L., Zhang, Y., Massacesi, C., Sahmoud, T., & Gianni, L. (January 2011). Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 125 (2), 447-455. doi:10.1007/s10549-010-1260-x

JERUSALEM, G., & SCHEEN, A. (2011). Editorial. Le cancer du sein. Revue Médicale de Liège, 66 (5-6), 225-228.

LIFRANGE, E., ANDRE, C., BLERET, V., BRADFER, J., CRISTINELLI, S., COUCKE, P., CUSUMANO, G., FRIDMAN, V., JERUSALEM, G., MARION, F., & COLIN, C. (2011). Prise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein. Revue Médicale de Liège, 66 (5-6), 329-335.

LIFRANGE, E., ANDRE, C., BLERET, V., COLLIGNON, J., COUCKE, P., CUSUMANO, G., DESREUX, J., HERMAN, P., JERUSALEM, G., KRIDELKA, F., MARTIN, M., RORIVE, A., Van Cauwenberge, J.-R., & COLIN, C. (2011). Hormonothérapie du cancer du sein. Revue Médicale de Liège, 66 (5-6), 367-371.

LOUSBERG, L., SOMJA, J., COLLIGNON, J., Gilles, C., & JERUSALEM, G. (2011). A propos d'un cas de rechute tardive de cancer du sein après traitement adjuvant. Revue Médicale de Liège, 66 (5-6), 306-310.

MARTIN, M., COLLIGNON, J., RORIVE, A., ANDRE, C., BOURHABA, M., ALLEPAERTS, S., COUCKE, P., LIFRANGE, E., & JERUSALEM, G. (2011). Le cancer du sein de la femme âgée. Revue Médicale de Liège, 66 (5-6), 400-408.

RORIVE, A., COLLIGNON, J., MARTIN, M., ANDRE, C., JERUSALEM, G., & COUCKE, P. (2011). Cancer du sein et métastases cérébrales. Revue Médicale de Liège, 66 (5-6), 299-305.

WITHOFS, N., COLLIGNON, J., RORIVE, A., JERUSALEM, G., & HUSTINX, R. (2011). Hétérogénéité des métastases osseuses du cancer du sein : cas clinique illustrant l'intérêt de combiner différentes techniques d'imagerie. Revue Médicale de Liège, 66 (5-6), 288-290.

Withofs, N., Grayet, B., Tancredi, T., Rorive, A., Mella, C., Giacomelli, F., Mievis, F., Aerts, J., Waltregny, D., Jerusalem, G., & Hustinx, R. (2011). 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nuclear Medicine Communications, 32 (3), 168-176. doi:10.1097/MNM.0b013e3283412ef5

Awada, A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Patel, T., Hannah, A. L., Masuoka, L. K., Garcia, A. A., & Perez, E. A. (December 2010). Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC). Cancer Research, 70 (24), 6-11-01.

Nechushtan, H., Edelman, G., JERUSALEM, G., Gordon, M., Kluger, H., Moussa, A., Ron, I., Schimmoller, F., Shen, X., & Daud, A. (November 2010). Phase 2 Results of XL184 in a Cohort of Patients with Advanced Melanoma. EJC Supplements, 8 (7), 126-127.

Collignon, J., Gennigens, C., & Jerusalem, G. (July 2010). Assessment of Response to Therapy for Bone Metastases : Is it still a challenge in oncology ? PET Clinics, 5 (3), 311-326. doi:10.1016/j.cpet.2010.05.002

Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126.

Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (07 January 2010). Het belang van de tumormarge na conservatieve chirurgie bij borstkanker in een vroeg stadium. Nederlandsch Tijdschrift voor Verloskunde en Gynaecologie, 6, 227-235.

Bleret, V., Collignon, J., Coucke, P., Cusumano, G., DESREUX, J., Herman, P., Jerusalem, G., Maweja, S., Remacle, N., Rorive, A., & Lifrange, E. (2010). L'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein. Revue Médicale de Liège, 65 (5-6), 405-408.

Capri, G., Chang, J., Chen, S. C., Conte, P., Cwiertka, K., Jerusalem, G., Jiang, Z., Johnston, S., Kaufman, B., Link, J., Ro, J., Schutte, J., Oliva, C., Parikh, R., Preston, A., Rosenlund, J., Selzer, M., Zembryki, D., & De Placido, S. (2010). An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology, 21 (3), 474-80. doi:10.1093/annonc/mdp373

Coucke, P., Jansen, N., Collignon, J., Janvary, Z. L., Rorive, A., Vanderick, J., & Jerusalem, G. (January 2010). Pourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ? Revue Médicale de Liège, 65 (1), 10-14.

Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Garnett, S., Lindemann, J. P. O., Sapunar, F., & Martin, M. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology, 28 (30), 4594-600. doi:10.1200/JCO.2010.28.8415

Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6.

JERUSALEM, G., Fasolo, A., Massacesi, C., Balaisius, M., Manlius, C., Sahmoud, T., Andre, F., & Gianni, L. (2010). Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies. Journal of Clinical Oncology, 28 (15s), 1041.

Coudert, B., Campone, M., Spielmann, M., Symann, M., Eichler, F., Serin, D., Delozier, T., Romieu, G., Canon, J.-L., Orfeuvre, H., Piot, G., Petit, T., Chollet, P., JERUSALEM, G., Audhuy, B., Veyret, C., Beauduin, M., Eymard, J.-C., Martin, A.-L., & Roché, H. (15 December 2009). Benefit of the sequential administration of Docetaxel after standard FEC regimen for node-positive breast cancer : long-term follow-up results of the FNCLCC-PACS 01 trial. Cancer Research, 69.

Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83.

Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (2009). Tumor Margin after conservative breast cancer surgery for early disease: an issue or not ? Belgian Journal of Medical Oncology, 3 (3), 93-100.

Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7.

GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13.

Jerusalem, G., & Withofs, N. (2009). Nuclear medicine imaging. In H.-J. Schmoll, L. Van't Veer, J. Vermorken, & D. Schrijvers (Eds.), ESMO Handbook of Cancer Diagnosis and Treatment Evaluation (pp. 29-36). Informa Healthcare.

Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81.

Van Vlaenderen, I., Canon, J. L., Cocquyt, V., Jerusalem, G., Machiels, J. P., Neven, P., Nechelput, M., Delabaye, I., Gyldmark, M., & Annemans, L. (2009). Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clinica Belgica, 64 (2), 100-12.

Coucke, P., Barthelemy, N., Jansen, N., Trivière, N., & Jerusalem, G. (February 2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter la radiothérapie pour certaines patientes opérées ? Revue Médicale de Liège, 63 (2), 75-81.

Coucke, P., Barthelemy, N., Jansen, N. (Other coll.), Triviere, N. (Other coll.), & Jerusalem, G. (Other coll.). (2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter les radiothérapie pour certaines patientes opérées? Revue Médicale de Liège, 63 (2), 75-81.

Hustinx, R., Jerusalem, G., & De Prijck, B. (2008). Tomographie à émission de positons et lymphomes. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 32, 449-455. doi:10.1016/j.mednuc.2008.06.002

WITHOFS, N., GRAYET, B., Tancredi, T., RORIVE, A., BECKERS, C., JERUSALEM, G., & HUSTINX, R. (2008). PET/CT for assessing bone involvement in prostate and breast cancer. Journal of Nuclear Medicine, 49 (SUPPL), 21.

Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8.

Giuliani, R., Durbecq, V., Di Leo, A., Paesmans, M., Larsimont, D., Leroy, J.-Y., Borms, M., Vindevoghel, A., Jerusalem, G., D'Hondt, V., Dirix, L., Canon, J.-L., Richard, V., Cocquyt, V., Majois, F., Reginster, M., Demol, J., Kains, J.-P., Delree, P., & Cardoso, F. (2007). Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). European Journal of Cancer, 43 (4), 725-35. doi:10.1016/j.ejca.2006.11.019

Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5.

Jerusalem, G., Withofs, N., Rorive, A., & Hustinx, R. (2007). Tomographie a emission de positons: un premier bilan. Revue du Praticien, 57 (17), 1864-70.

Jerusalem, G., Silvestre, R., Beguin, Y., Hustinx, R., Fassotte, M.-F., & Fillet, G. (20 June 2006). FDG-PET for the routine follow-up in NHL: First prospective evaluation. Journal of Clinical Oncology, 24 (18, Part 1 Suppl. S), 439.

Couturier, O., Jerusalem, G., N'Guyen, J.-M., & Hustinx, R. (2006). Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clinical Cancer Research, 12 (21), 6437-43. doi:10.1158/1078-0432.CCR-06-0383

Jerusalem, G., & Beguin, Y. (2006). The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica, 91 (4), 442-4.

Jerusalem, G., & Hustinx, R. (2006). The lymphomas. Nuclear Medicine. In G. P. Canellos, A. T. Lister, & B. Young, The lymphomas (pp. 189-202). Philadelphia, United States: Saunders.

Jerusalem, G., Hustinx, R., & Rigo, P. (2006). PET and PET/CT imaging in lymphomas. In P. E. Valk, D. Delbeke, D. L. Bailey, D. W. Townsend, & M. N. Maisey, Positron emission tomography (pp. 125-145). Londres, United Kingdom: Springer.

Jerusalem, G., Rorive, A., Ancion, G., Hustinx, R., & Fillet, G. (2006). Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Annals of Oncology, 17 Suppl 10, 168-76. doi:10.1093/annonc/mdl255

Depas, G., De Barsy, C., Jerusalem, G., Hoyoux, C., DRESSE, M.-F., Fassotte, M.-F., Paquet, N., Willems, J., Rigo, P., & Hustinx, R. (January 2005). F-18-FDG PET in children with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 32 (1), 31-38. doi:10.1007/s00259-004-1604-z

Focan, C., Graas, M. P., Beauduin, M., Canon, J. L., Salmon, J.-P., Jerusalem, G., Focan-Henrard, D., Lobelle, J. P., & Schallier, D. (2005). Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Anticancer Research, 25 (2B), 1211-7.

Jerusalem, G., & Belhocine, T. Z. (2005). Metabolic monitoring of chemosensitivity with 18FDG PET. Methods in Molecular Medicine, 111, 417-40. doi:10.1385/1-59259-889-7:417

Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Whole-Body Positron Emission Tomography using 18F-Fluorodeoxyglucose for Staging Response Assessment in Hodgkin's Disease. In B. C. Heinz (Ed.), Trends in Hodgkin's Disease Research (pp. 169-188). New York, United States: Nova Science Publishers.

Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Positron emission tomography imaging for lymphoma. Current Opinion in Oncology, 17 (5), 441-5. doi:10.1097/01.cco.0000174041.29557.5c

Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2005). Evaluation of therapy for lymphoma. Seminars in Nuclear Medicine, 35 (3), 186-96. doi:10.1053/j.semnuclmed.2005.02.004

Polus, M., Piront, P., Jerusalem, G., Sautois, B., Defechereux, T., de Leval, L., & Fillet, G. (February 2004). L'image du mois. Tumeur de Merkel : reponse majeure a la chimiotherapie. "Il n'y a pas que la neige qui fond au soleil". Revue Médicale de Liège, 59 (2), 67-8.

Baron, F., Copizza, S., Baudoux, E., Jerusalem, G., Fillet, G., & Beguin, Y. (2004). CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Haematologica, 89 (9), 1146-8.

Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21.

Jerusalem, G., & Hustinx, R. (15 October 2003). Tomographie a emission de positons: une revolution en cancerologie? Revue du Praticien, 53 (15), 1629-30.

Hustinx, R., Lemaire, C., Jerusalem, G., Moreau, P., Cataldo, D., Duysinx, B., Aerts, J., Fassotte, M.-F., Foidart, J., & Luxen, A. (April 2003). Whole-body tumor imaging using PET and 2-18F-fluoro-l-tyrosine: Preliminary evaluation and comparison with 18F-FDG. Journal of Nuclear Medicine, 44 (4), 533-539.

Polus, M., Piront, P., Jerusalem, G., Sautois, B., Louis, E., Detroz, B., Laurent, S., Belaiche, J., & Fillet, G. (April 2003). Prevention primaire et secondaire du cancer colorectal. Revue Médicale de Liège, 58 (4), 247-53.

Andre, M., Baudoux, E., Bron, D., Canon, J.-L., D'Hondt, V., Fassotte, M.-F., D'Hondt, L., Fillet, G., Humblet, Y., Jerusalem, G., Vermeulen, P., Symann, M., & Beguin, Y. (2003). Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion, 43 (1), 50-7. doi:10.1046/j.1537-2995.2003.00273.x

DE BARSY, DEPAS, G., DRESSE, M.-F., HOYOUX, C., SCHMITZ, V., JERUSALEM, G., FASSOTTE, M.-F., FOIDART-WILLEMS, J., & HUSTINX, R. (2003). Whole-body FDG PET in the follow-up of pediatric patients with lymphoma. Journal of Nuclear Medicine, 44, 346.

DE BARSY, DEPAS, G., DRESSE, M.-F., HOYOUX, C., SCHMITZ, V., JERUSALEM, G., FASSOTTE, M.-F., FOIDART-WILLEMS, J., & HUSTINX, R. (2003). Whole-body FDG PET imaging as a method for staging and early assessment of treatment response in pediatric patients with lymphoma. Journal of Nuclear Medicine, 44, 183.

Hustinx, R., Sautois, B., Jerusalem, G., & Foidart, J. (2003). Radiothérapie métabolique des douleurs osseuses métastatiques. Médecine et Hygiène, 61, 1560-1564.

Jerusalem, G., Beguin, Y., Fassotte, M.-F., Belhocine, T., Hustinx, R., Rigo, P., & Fillet, G. (2003). Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Annals of Oncology, 14 (1), 123-30. doi:10.1093/annonc/mdg011

Jerusalem, G., Hustinx, R., Beguin, Y., Depas, G., Fassotte, M.-F., De Barsy, C., Foidart, J., & Fillet, G. (2003). Les lymphomes. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 27 (8), 401-410.

Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2003). PET scan imaging in oncology. European Journal of Cancer, 39 (11), 1525-34. doi:10.1016/S0959-8049(03)00374-5

Jerusalem, G., & Rigo, P. (2003). PET Imaging in Lymphoma. In P. E. Valk, D. L. Bailey, D. W. Townsend, & M. N. Maisey (Eds.), Positron emission tomography (pp. 547-557). Springer.

Jerusalem, G., Rigo, P., & Israel, O. (2003). PET and PET/CT of lymphoma. In G. K. von Schulthess (Ed.), Clinical Molecular Anatomic Imaging (pp. 350-361). Lippincott Williams and Wilkins.

Pelerin, D., Silvestre, R. M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (December 2002). Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene. Revue Médicale de Liège, 57 (12), 755-6.

Polus, M., Honore, P., De Roover, A., Detry, O., Detroz, B., Jerusalem, G., Sautois, B., & Fillet, G. (December 2002). La carcinomatose hepatique du cancer colorectal: actualites therapeutiques. Revue Médicale de Liège, 57 (12), 771-8.

Belhocine, T., Steinmetz, N., Hustinx, R., Bartsch, P., Jerusalem, G., Seidel, L., Rigo, P., & Green, A. (September 2002). Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clinical Cancer Research, 8 (9), 2766-2774.

Polus, M., Bours, V., Jerusalem, G., Sautois, B., & Fillet, G. (July 2002). Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles. Revue Médicale de Liège, 57 (7), 428-32.

Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., & Fillet, G. (March 2002). Comment je traite.... Un cancer du pancreas avance. Revue Médicale de Liège, 57 (3), 131-4.

Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., Collette, M. Y., Closon, M. T., & Fillet, G. (February 2002). Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1. Revue Médicale de Liège, 57 (2), 119-22.

Brasseur, E., Silvestre, R.-M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (2002). Prévention et traitement des nausées et vomissements après chimiothérapie anticancéreuse. Médecine et Hygiène, 60, 1509-1513.

HUSTINX, R., Lemaire, C., JERUSALEM, G., MOREAU, P., Cataldo, D., DUYSINX, B., Aerts, J., & Luxen, A. (2002). 18F-fluoro-L-tyrosine : a potential tracer for whole-body tumor imaging with PET. Journal of Nuclear Medicine, 43, 77.

Jerusalem, G., & Beguin, Y. (2002). Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clinical Lymphoma, 3 (1), 56-61. doi:10.3816/CLM.2002.n.012

Jerusalem, G., & Beguin, Y. (2002). Does positron emission tomography have a role in routine clinical practice in patients with Hodgkin's disease? Clinical Lymphoma, 3 (2), 125-6. doi:10.1016/S1526-9655(11)70258-5

Jerusalem, G., & Beguin, Y. (2002). Commentary on "Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?". Clinical Lymphoma, 2 (4), 249. doi:10.1016/S1526-9655(11)70232-9

Jerusalem, G., Hustinx, R., Beguin, Y., & Fillet, G. (2002). The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Annals of Oncology, 13 Suppl 4, 227-34. doi:10.1093/annonc/mdf664

Warland, V., Jerusalem, G., Hustinx, R., Beguin, Y., Silvestre, R. M., Fassotte, M.-F., Foidart, J., & Fillet, G. (2002). Comment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee? Revue Médicale de Liège, 57 (12), 779-84.

Najjar, F., Hustinx, R., Jerusalem, G., Fillet, G., & Rigo, P. (August 2001). Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL). Cancer Biotherapy and Radiopharmaceuticals, 16 (4), 297-304. doi:10.1089/108497801753131372

Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2001). Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica, 86 (3), 266-73.

Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M.-F., Rigo, P., & Fillet, G. (2001). Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Annals of Oncology, 12 (6), 825-30. doi:10.1023/A:1011169332265

Jerusalem, G., Belhocine, T., Silvestre, R.-M., Sautois, B., Hustinx, R., Beguin, Y., Fillet, G., & Rigo, P. (2001). Place de la tomographie d'émission de positons dans le suivi thérapeutique du cancer du sein. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 25 (6), 341-346.

Sylvestre, R.-M., Jerusalem, G., Sautois, B., Beguin, Y., & Fillet, G. (2001). Nouvelles approches thérapeutiques puor l'hypernéphrome métastasique. Médecine et Hygiène, 59, 1607-1609.

JERUSALEM, G., & BEGUIN, Y. (June 2000). Commentary on "Positron emission tomography in lymphoma : comparison with computed tomography and Gallium-67 single photon emission computed tomography imaging". Clinical Lymphoma, 1 (1), 75-76.

Jerusalem, G., Bours, V., & Fillet, G. (May 2000). Traitement adjuvant du cancer du sein: meta-analyse et recommandations therapeutiques. Revue Médicale de Liège, 55 (5), 356-9.

Jerusalem, G., Bours, V., & Fillet, G. (March 2000). Existe-t-il des progres dans le traitement du cancer du pancreas metastatique? Revue Médicale de Liège, 55 (3), 146-8.

BELHOCINE, T., HUSTINX, R., JERUSALEM, G., FASSOTTE, M.-F., DUYSINX, B., QUADEN, C., & RIGO, P. (2000). 99mTc rh-Annexin V (ApomateTM) as a marker of apoptosis resulting from chemotherapy : preliminary results. Journal of Nuclear Medicine, 41 (SUPPL), 263.

Bonnet, C., Jerusalem, G., Bours, V., & Fillet, G. (2000). Approches thérapeutiques du cancer ovarien. Médecine et Hygiène, 58, 1625-1628.

Fraipont, V., Sautois, B., Baudoux, E., Pereira-Martins, M., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Longree, L., Schaaf-Lafontaine, N., Fillet, G., & Beguin, Y. (2000). Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion, 40 (3), 339-47. doi:10.1046/j.1537-2995.2000.40030339.x

Jerusalem, G., & Beguin, Y. (2000). Clinical impact and perspectives of 18F-FDG PET in lymphoma. Clinical Lymphoma, 1, 75-76.

JERUSALEM, G., BEGUIN, Y., FASSOTTE, M.-F., BELHOCINE, T., HUSTINX, R., RIGO, P., & FILLET, G. (2000). Early detection of relapse by whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) in the follow-up of patients with Hodgkin’s disease (HD). PROCEEDINGS OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2000, 19, 10.

Jerusalem, G., Beguin, Y., Fassotte, M.-F., Belhocine, T., Najjar, F., Hustinx, R., Rigo, P., & Fillet, G. (2000). Evaluation thérapeutique précoce par tomographie à émission de positons. Médecine et Hygiène, 58, 1629-1632.

Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2000). Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85 (6), 613-8.

NAJJAR, F., HUSTINX, R., JERUSALEM, G., FILLET, G., & RIGO, P. (2000). Whole-body 18FDG-PET for staging low grade non Hodgkin’s lymphoma. European Journal of Nuclear Medicine, 27, 1159.

Jerusalem, G. (1999). Place de la tomographie à émission de positons au 18F-FDG dans le bilan d'extension, l'évaluation thérapeutique précoce et le suivi des patients atteints de lymphomes hodgkiniens et non-hodgkiniens. Unpublished doctoral thesis, ULiège - Université de Liège.
Jury: Fillet, G. (Promotor).

Jerusalem, G., Beguin, Y., Fassotte, M.-F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94 (2), 429-33. doi:10.1182/blood.v94.2.429.414k26_429_433

Jerusalem, G., Bours, V., & Fillet, G. (1999). Actualités thérapeutiques dans le traitement du cancer colorectal. Médecine et Hygiène, 57, 1552-1554.

Jerusalem, G., Warland, V., Najjar, F., Paulus, P., Fassotte, M. F., Fillet, G., & Rigo, P. (January 1999). Whole-Body 18f-Fdg Pet for the Evaluation of Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma. Nuclear Medicine Communications, 20 (1), 13-20. doi:DOI:10.1080/00006231-199901000-00004

Najjar, F., Jerusalem, G., Paulus, P., Fillet, G., & Rigo, P. (1999). Intérêt clinique de la tomographie à émission de positons dans la détection et le bilan d'extension des lymphomes non Hodgkiniens de malignité intermédiaire ou élevée. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 23, 281-290.

Rezaei Kalantari, H., Jerusalem, G., Bours, V., & Fillet, G. (January 1999). Les tumeurs malignes d'origine indéterminée. Revue Médicale de Liège, 54 (1), 39-42.

Sautois, B., Fraipont, V., Baudoux, E., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Bours, V., Bosquee, L., Schaaf-Lafontaine, N., Paulus, J.-M., Sondag, D., Fillet, G., & Beguin, Y. (1999). Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica, 84 (4), 342-9.

Jerusalem, G., Bours, V., & Fillet, G. (June 1998). Pharma-clinics. Comment je traite... II. Approche thérapeutique du cancer colorectal métastatique. Revue Médicale de Liège, 53 (6), 318-21.

Jerusalem, G., Bours, V., & Fillet, G. (May 1998). Traitement du cancer colorectal. Aspects pharmaco-économiques. Revue Médicale de Liège, 53 (5), 276-8.

Bours, V., Jerusalem, G., & Fillet, G. (April 1998). Comment je traite ... Le cancer colorectal: I. Prévention et traitement adjuvant. Revue Médicale de Liège, 53 (4), 167-70.

Hustinx, R., Paulus, P., Jacquet, N., Jerusalem, G., Bury, T., & Rigo, P. (1998). Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Annals of Oncology, 9 (4), 397-401. doi:10.1023/A:1008290027419

Pierard, G., Nikkels, N., Nikkels, A., Arrese Estrada, J., Pierard, C., Jerusalem, G., Beguin, Y., & Fillet, G. (1998). Epidermal Calprotectin Expression in Lymphocyte-Depleted Cutaneous Graft-versus-Host Reaction. Archivos Argentinos de Dermatologia, 48, 139-142.

Jerusalem, G., & Fillet, G. (April 1997). Problèmes diagnostiques, thérapeutiques et socio-économiques en oncologie gériatrique. Revue Médicale de Liège, 52 (4), 255-7.

Jerusalem, G. (1997). Actualisation du traitement des cancers du sein. Chimiothérapie myéloblastique et greffes de cellules souches hématopoiétiques. Revue Médicale de Liège, 52 (2), 76-9.

Jerusalem, G., & Fillet, G. (1997). Les taxanes : un nouvelle classe d'agents cytotoxiques. Médecine et Hygiène, 55, 1501-1504.

Rigo, P., Paulus, P., Bury, T., Jerusalem, G., Hustinx, R., Benoit, T., Larock, M.-P., & Foidart, J. (1997). Clinical PET in oncology. Radioactive Isotopes in Clinical Medicine Research XXII.

Rigo, P., Paulus, P., Bury, T., Jerusalem, G., Hustinx, R., Benoit, T., Larock, M.-P., & Willems, J. (1997). Clinical PET in Oncology. In H. Bergmann, A. Kroiss, & Sinzinger H (Eds.), Radioactive Isotopes in Clinical Medicine and Research (pp. 3-14). Basel, Switzerland: Birhauser Verlag.

Rigo, P., Paulus, P., Kaschten, B., Hustinx, R., Bury, T., Jerusalem, G., Benoit, T., & Foidart-Willems, J. (December 1996). Oncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose. European Journal of Nuclear Medicine, 23 (12), 1641-74. doi:10.1007/BF01249629

HUSTINX, R., PAULUS, P., DAENEN, F., JERUSALEM, G., JACQUET, N., & RIGO, P. (May 1996). PET imaging of liver metastases: a retrospective study. Journal of Nuclear Medicine, 37, 250P-251.

HUSTINX, R., PAULUS, P., BENOIT, T., JERUSALEM, G., JACQUET, N., & RIGO, P. (1996). Clinical value of whole body-body PET-FDG in the detection of liver metastases: preliminary results. European Journal of Nuclear Medicine, 23, 1110.

Jerusalem, G., Detroz, B., Herman, P., Dohogne, A., Closon, M. T., Jacquet, N., Honoré, P., Bruyninx, L., Fillet, G., Fassotte, M.-F., Bours, V., & Lipcsei, G. (1995). Approche thérapeutique du cancer épithélial de l'ovaire au CHU Sart Tilman : Conclusions de la réunion interdisciplinaire du 22 mars 1995. Revue Médicale de Liège, 50, 469-471.

Rigo, P., Paulus, P., JERUSALEM, G., BURY, T., Deneufbourg, J.-M., Depas, G., Benoît, T., Larock, M.-P., & Foidart, J. (1995). Indications cliniques de la tomographie à positons au 18FDG en oncologie. Expérience préliminaire et revue de la littérature. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 19, 73-89.